0001213900-22-045945.txt : 20220809 0001213900-22-045945.hdr.sgml : 20220809 20220809165302 ACCESSION NUMBER: 0001213900-22-045945 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 44 CONFORMED PERIOD OF REPORT: 20220531 FILED AS OF DATE: 20220809 DATE AS OF CHANGE: 20220809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Better For You Wellness, Inc. CENTRAL INDEX KEY: 0001852707 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-56262 FILM NUMBER: 221149158 BUSINESS ADDRESS: STREET 1: 1349 EAST BROAD STREET CITY: COLUMBUS STATE: OH ZIP: 43205 BUSINESS PHONE: 6143689898 MAIL ADDRESS: STREET 1: 1349 EAST BROAD STREET CITY: COLUMBUS STATE: OH ZIP: 43205 FORMER COMPANY: FORMER CONFORMED NAME: Fast Track Solutions, Inc. DATE OF NAME CHANGE: 20210322 10-Q 1 f10q0522_betterforyou.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE QUARTERLY PERIOD ENDED May 31, 2022

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

COMMISSION FILE NUMBER: 000-56262

  

better for you wellness, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   87-2903933

(State or other jurisdiction of
incorporation or organization)

  (I.R.S. Employer
Identification No.)
     

c/o Jeffrey DeNunzio

1349 East Broad Street

Columbus, OH

  43205
(Address of Principal Executive Offices)   (Zip Code)

 

(614) 368-9898
(registrant’s telephone number, including area code)

 

N/A
(former name or former mailing address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbols   Name of each exchange on which registered
None   None   None

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   Accelerated filer   Non-accelerated filer
Smaller reporting company   Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes No

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

As of August 4, 2022, there were 385,198,451 shares of Common Stock and 700,000 shares of Series A Preferred Stock issued and outstanding. 

 

 

 

 

 

 

INDEX

 

    Page 
PART I - FINANCIAL INFORMATION  
   
ITEM 1 FINANCIAL STATEMENTS - UNAUDITED 1
  CONSOLIDATED Balance Sheets - UNAUDITED 1
  CONSOLIDATED Statements of Operations- UNAUDITED  2
  STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) - UNAUDITED  3
  CONSOLIDATED Statement of Cash Flows - unaudited 5
  Notes to Financial Statements - unaudited 6
     
ITEM 2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS 18
ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 29
ITEM 4 CONTROLS AND PROCEDURES 29
 
PART II - OTHER INFORMATION  
 
ITEM 1 LEGAL PROCEEDINGS 30
ITEM 1A RISK FACTORS 30
ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 30
ITEM 3 DEFAULTS UPON SENIOR SECURITIES 30
ITEM 4 MINE SAFETY DISCLOSURES 30
ITEM 5 OTHER INFORMATION 30
ITEM 6 EXHIBITS 30
   
SIGNATURES 31

 

i

 

 

PART I - FINANCIAL INFORMATION

 

Better For You Wellness, Inc.

Consolidated Balance Sheet

 

   May  31,
2022
   February 28,
2022
 
         
ASSETS        
Cash  $2,695   $9,719 
Inventory   7,037    13,106 
Total Current Assets   9,732    22,825 
Equipment, net depreciation   607    731 
TOTAL ASSETS  $10,338   $23,555 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
CURRENT LIABILITIES          
Loans to company – related party  $306,738   $305,666 
Convertible note payable, net accumulated interest   315,063    - 
Loans payable, other   -    5,385 
Stock Warrant liability   36,366    - 
Other current liabilities   119    11,150 
Accrued Expenses  $16,217   $172,933 
           
TOTAL LIABILITIES  $674,503   $495,133 
           
Stockholders’ Equity (Deficit)          
Preferred stock ($.0001 par value, 200,000,000 shares authorized; 700,000 issued and outstanding as of May 31, 2022 and February 28, 2022)   70    70 
Common stock ($.0001 par value, 500,000,000 shares authorized, 380,108,169 and 370,747,042issued and outstanding as of May 31, 2022 and February 28, 2022, respectively)
   38,011    37,075 
Shares Cancelable   
-
    (250,000)
Additional paid-in capital   2,419,264    1,485,364 
Noncontrolling interest   
-
    4,358 
Accumulated deficit   (3,121,510)   (1,748,445)
Total Stockholders’ Equity (Deficit)   (664,165)   (471,578)
           
TOTAL LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT)  $10,338   $23,555 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

1

 

 

Better For You Wellness, Inc.

Consolidated Statement of Operations

 

   Three Months
May 31,
2022
   Three Months
May 31,
2021
 
         
Revenue 
 
  
 
 
Merchandise Sales  $13,087   $19,455 
Cost of Goods Sold   10,268    7,230 
Gross Profit  $2,819   $12,226 
Operating Expenses:          
Selling, general and administrative expenses  $240,576   $23,692 
Impairment expense   577,473    
-
 
Share-based expense   516,407    70,000 
Total operating expenses   1,334,455    93,692 
           
Other Income          
Other income  $
-
   $10 
Stock warrant expense   (36,366)   
-
  
Other expense   (5,063)   (21)
Total other income(expense)   (41,429)   (11)
           
Net loss  $(1,373,066)  $(81,477)
           
Basic and Diluted net loss per common share
  $(0.00)  $(0.00)
           
Weighted average number of common shares outstanding - Basic and Diluted
   363,657,794    195,652,174 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

2

 

 

Better For You Wellness, Inc.

Statement of Changes in Stockholders’ Equity (Deficit)

For the Period Ended May 31, 2022

(Unaudited)

 

   Common
Shares
   Par
Value
Common
Shares
  

Series A

Preferred
Shares

   Par
Value
Series A
Preferred
Shares
   Additional
Paid-in
Capital
  

 

 

 

Shares
Cancelable

  

 

 

 

Noncontrolling
Interest

   Accumulated
Deficit
   Total 
                                     
Balances, February 28, 2022   370,747,042   $37,075    700,000   $70   $1,485,364   $(250,000)  $4,358   $(1,748,445)  $(471,578)
Common shares canceled and returned to the Company   (7,048,873)   (705)   -    -    (249,295)   250,000    -    -    - 
Common shares issued for shares payable   325,000    33    -    -    (33)   -    -    -    - 
Common shares issued for services   5,085,000    509    -    -    253,742    -    -    -    254,250 
Common shares issued for purchase of subsidiary   11,000,000    1,100    -    -    576,373    -    -    -    577,473 
Stock option expense   -    -    -    -    262,157    -    -    -    262,157 
Expenses paid on behalf of the Company and contributed to capital   -    -    -    -    90,956    -    -    -    90,956 
Noncontrolling interest   -    -    -    -    -    -    (4,358)   -    - 
Net loss   -    -    -    -    -    -    -    (1,373,066)   (1,373,066)
Balances, May 31, 2022   380,108,169    $38,011    700,000   $70   $2,419,264   $-   $-   $(3,121,510)  $(664,165)

 

The accompanying notes are an integral part of these unaudited financial statements.

 

3

 

 

Better For You Wellness, Inc.

Statement of Changes in Stockholders’ Equity (Deficit)

For the Period Ended May 31, 2021

(Unaudited)

 

   Common
Shares
   Par
Value
Common
Shares
   Series A
Preferred
Shares
   Par
Value
Series A
Preferred
Shares
   Additional
Paid-in
Capital
  

 

 

 

Noncontrolling
Interest

   Accumulated
Deficit
   Total 
                                 
Balances, February 28, 2021   -   $-    -   $-   $1,185   $-   $(57,150)  $(55,965)
                                         
Common shares issued after reorganization   359,996,332    36,000    -    -    (36,000)   -    -    - 
Series A preferred shares issued after reorganization   -    -    700,000    700    69,930         -    70,000 
Expenses paid on behalf of the Company and contributed to capital   -    -    -    -    3,951    -    -    3,951 
Noncontrolling interest   -    -    -    -    -    20,768    -    20,768 
Net loss   -    -    -    -    -         (81,477)   (81,477)
Balances, May 31, 2021   359,996,332    $36,000    700,000   $700   $39,066    20,768   $(138,627)  $(42,723)

 

The accompanying notes are an integral part of these unaudited financial statements.

 

4

 

 

Better For You Wellness, Inc.

Consolidated Statement of Cash Flows

 

  

Three Months
May 31,
2022

   Three Months
May 31,
2021
 
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss  $(1,373,066)  $(81,477)
Adjustment to reconcile net loss to net cash used in operating activities:          
Common stock issued   254,250    
-
 
Preferred stock issued   -    70,000 
Impairment expense   577,473    - 
Warrant expense   36,366    - 
Stock options expense   262,157    
-
 
Amortized interest   5,063    - 
Changes in current assets and liabilities:          
Accrued expenses   (156,716)   (2,630)
Notes payable   (5,385)   (15,039)
Stock warrant liability   89,286    - 
Other current liabilities   (10,893)   32 
Net cash used in operating activities   (404,695)   (30,358)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Convertible note payable  $310,000   $
-
 
Noncontrolling interest   (4,358)   20,768 
Expenses contributed to capital   90,956    3,951 
Loan to company – related party   1,072    
-
 
Net cash provided by financing activities   397,671    24,719 
Net change in cash  $(7,024)  $(5,640)
Beginning cash balance   9,719    8,348 
Ending cash balance  $2,695   $2,708 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:          
Interest paid  $
-
   $
-
 
Income taxes paid  $
-
   $
-
 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

5

 

 

Better For You Wellness, Inc.

Notes to Unaudited Consolidated Financial Statements

 

Note 1 - Organization and Description of Business

 

Better For You Wellness, Inc. (“we,” “us,” “our”, the “Company” or the “Registrant”) was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.

 

On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Our former director, Jeffrey DeNunzio, was the sole director/officer of each constituent corporation in the Reorganization.

 

Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.

 

Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021, at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.

 

Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until the new ticker symbol “FTRK” for the Company was released into the OTC MarketPlace on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.

 

The Company believes that the Reorganization, deemed effective on May 5, 2021, was not a transaction of the type described in subparagraph (a) of Rule 145 under the Securities Act of 1933 and the consummation of the Reorganization will not be deemed to involve an “offer”, “offer to sell”, “offer for sale” or “sale” within the meaning of Section 2(3) of the Securities Act of 1933. The Reorganization was consummated without the vote or consent of the Company’s stockholders. In addition, the provisions of NRS 92A.180 did not provide a stockholder of the Company with appraisal rights in connection with the Reorganization. The Company believes that in the absence of any right of any of the Company’s stockholders to vote with respect to the Reorganization or to insist that their shares be purchased for fair value, the Reorganization could not be deemed to involve an “offer” “offer to sell”; or “sale” within the meaning of Section 2(3) of the Securities Act of 1933.”

 

On May 5, 2021, after the completion of the Holding Company Reorganization, we canceled all of the stock we held in Sauer Energy, Inc., resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.

 

Given that the former business plan and objectives of Sauer Energy, Inc. and the business plan and objectives of Fast Track Solutions, Inc. substantially differed from one another, we conducted the corporate separation with Sauer Energy, Inc. immediately after the effective time of the Reorganization in order to avoid any shareholder confusion. The former business plan of Sauer Energy, Inc. (the development and marketing of wind powered electric generators) under the leadership of its former directors, did not, in any way, represent the blank check business plan of Fast Track Solutions, Inc. at that time, and thus it is the belief of the Company that the corporate separation ameliorated shareholder confusion about our identity and/or corporate objectives. It is our belief that Sauer Energy was a shell company at the time of the Reorganization.

 

6

 

 

The corporate actions taken by the Company, including, but not limited to, the corporate structuring of the transactions, was deemed, in the discretion of our sole director, to be for the benefit of the corporation and its shareholders. Former shareholders of Sauer Energy, Inc. were then the shareholders of Fast Track Solutions, Inc. and had the opportunity to benefit from a business combination with another company. The Company intended to serve as a vehicle to affect an asset acquisition, merger, exchange of capital stock or other business combination with a domestic or foreign business at that time

  

After the reorganization and through July 18, 2021, CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody, was our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock.

 

On July 19, 2021, Better For You Wellness, Inc., FKA “Fast Track Solutions, Inc.”, a Nevada Corporation (the “Company”), entered into a Share Purchase Agreement (the “Agreement”) by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021 (“Closing Date”), CRS sold 700,000 shares of the Company’s Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of the Company; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000) (the “Purchase Price”). The consummation of the transactions contemplated by the Agreement resulted in a change in control of the Company, with GOHV, Ian James, and Stephen Letourneau, becoming the Company’s largest controlling stockholders having approximately 89.62% combined voting control over the Company.

 

Pursuant to the Agreement, on July 30, 2021, Mr. Jeffrey DeNunzio resigned as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Director.

 

On July 30, 2021, Mr. Ian James was appointed as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors and Mr. Stephen Letourneau was appointed as a Director.

 

On August 19, 2021, the Company filed an 8-K with the SEC to disclose an amendment to the Company’s Articles of Incorporation that the Company filed on August 18, 2021, with the Nevada Secretary of State to change its name to Better For You Wellness, Inc. Within the aforementioned 8-K, the Company disclosed that, at the time, it was pending a FINRA corporate action to affect the name change on the OTC to Better For You Wellness, Inc., and also a ticker symbol change. FINRA announced, on their September 29, 2021 daily list, that the market effective date of our name change, and ticker symbol change, will be September 30, 2021. On September 30, 2021, we will begin trading under the symbol BFYW. The new CUSIP number associated with our common stock, as of the market effective date of September 30, 2021, is 08771B105.

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided. This transaction did not result in MRKTS Group Inc. owning 5% or more of any class of securities of the issuer.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau. The aforementioned transaction(s) did not result in any individual shareholder owning 5% or more of any class of securities of the issuer. The aforementioned transaction was carried out as it was deemed by GOHV to be in the best interests of its members.

 

On August 27, 2021, Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company.

 

On September 1, 2021, we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per annum, paid in equal $250 distributions quarterly, and 200,000 shares of common stock, issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share. The Directors were officially seated September 12, 2021, after notification to shareholders. On December 14, 2021, the Company’s Board of Directors unanimously approved the appointment of Christina Jefferson to the Board as an Independent Director, effective January 1, 2022. Christina Jefferson replaced Leslie Bumgarner whose resignation, as previously announced, became effective December 31, 2021.

 

7

 

 

On February 3. 2022, the Company was approved by OTC Markets to up-list its common stock from the OTC Pink Sheets to the OTCQB® Venture Market (the “OTCQB”). The Company began trading of its common shares on the OTCQB as of the market open on February 3, 2022, under its same symbol, “BFYW.”

 

On February 5, 2022, the Company’s Board of Directors unanimously approved the establishment of a Strategic Advisory Committee. The Board appointed six initial members by unanimous consent including David King, Laurie Racine, Zhiping Zhang, Melisse Gelula, Christopher Brown, and Kate Hendrickson.

 

Also on February 5, 2022, by unanimous vote of the Company’s Board of Directors’ five non-executive Independent Directors, David Deming was appointed Chairperson of the Company’s Audit Committee, which follows the Board’s October 1, 2021, unanimous consent to establish the Audit Committee. The Audit Committee currently consists of three non-executive Independent Directors, including Montel Williams, Joseph Watson, and David Deming. Also, by unanimous vote of the Board’s five non-executive Independent Directors, Christina Jefferson was appointed to the Company’s Compensation Committee, filling the vacancy left by former Director Leslie Bumgarner. This action follows the Board’s October 1, 2021, unanimous consent to establish the Compensation Committee. The Compensation Committee currently consists of Independent Directors, Christina Jefferson, Montel Williams, and Joseph Watson. Additionally, the Board’s five non-executive Independent Directors unanimously appointed Joseph Watson as Chairperson of the Compensation Committee.

 

The Company’s current business plan is to explore and evaluate various opportunities in the plant-based food and beverage and consumer packaged goods sectors, including but not limited to, mergers, acquisitions, or business combination transactions, after which the Company would cease to be a “shell” or “blank check” company. The Company’s principal business objective for the next 12 months and beyond will be to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings.

 

On November 15, 2021, the Company’s wholly owned subsidiary, Glow Market, LLC was formed in the State of Ohio. Subsequently, Glow Market, LLC launched its first brand, Better Suds, an online retailer of specialty all-natural, cruelty-free, gluten-free and chemical-free soaps. Better Suds commenced operations in December 2021.

 

On April 29, 2022 the Company entered into a Membership Interest Purchase Agreement (the “MIPA”) with Amanda Cayemitte and Yapo M’be (referred to together as the “Sellers”) to acquire the right, title and interest in, including all of the outstanding membership interests (referred to together as the “MM Interests”) of Mango Moi, LLC (“Mango Moi”).

 

Mango Moi is a hair and skincare business located in Chicago, Illinois. Pursuant to the MIPA, in exchange for the MM Interests, the Company agreed to pay the Sellers a purchase price consisting of shares of the Company’s common stock, par value $0.0001 per share which consists of 11,000,000 shares of common stock (the “Company Common Stock”), with a fair market value of approximately $550,000, with 5,720,000 shares of Company Common Stock issued to Amanda Cayemitte and 5,280,000 shares of Company Common Stock issued to Yapo M’be (referred to together herein as the “Purchase Price”). Additionally, pursuant to the terms of the MIPA, the Company agreed to enter into an Employment Agreement with Mango Moi founder Amanda Cayemitte (the “Employment Agreement”), and a Consulting Agreement with Yapo M’be  (the “Consulting Agreement”), respectively, as disclosed by the Company on its Current Report on Form 8-K filed with the SEC on May 2, 2022.

 

The MIPA closed (the “Closing”) on May 26, 2022, on which date the Company paid the Sellers the Purchase Price by issuing the Company Common Stock to the Sellers and the Sellers transferred the MM Interests to the Company, and on which date Mango Moi became a wholly owned subsidiary of the Company. At the Closing the Company entered into the Employment Agreement with Amanda Cayemitte and the Consulting Agreement with Yapo M’be.

 

8

 

 

The Company intends to optimize Mango Moi’s product formulae and packaging, as well as secure new manufacturing relationships to scale production capacity. Additionally, the Company plans to expand Mango Moi’s product offerings to include additional products and product bundles. Furthermore, the Company intends to grow sales through direct-to-consumer marketing efforts, subscription box sales, and pursuing wholesale sales relationships. 

 

The Company’s main office is located at 1349 East Broad Street, Columbus OH 43205.

 

The Company has elected February 28th as its year end.

  

Note 2 - Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Glow Markets, LLC and Mango Moi, LLC. All significant intercompany accounts and transactions have been eliminated.

 

Basis of Presentation

 

This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at May 31, 2022 and February 28, 2022 were $2,695 and $9,719 respectively. 

 

Revenue recognition

 

The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

 

Revenue for products is recognized when the products are delivered to the customer and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of May 31, 2022, the Company had no deferred revenues. 

 

Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.”  Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs.  A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at May 31, 2022.

 

9

 

 

Basic Earnings (Loss) Per Share

 

The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company does not have any potentially dilutive instruments as of May 31, 2022 and, thus, anti-dilution issues are not applicable.

 

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

 

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.  

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.

 

Related Parties

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

Share-Based Compensation

 

ASC 718, “Compensation – Stock Compensation”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

10

 

 

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.”  Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable:  (a) the goods or services received; or (b) the equity instruments issued.  The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.  

 

The Company had no stock-based compensation plans as of May 31, 2022 and February 28, 2022.

 

The Company’s stock-based compensation for the period ended May 31, 2022 and May 31, 2021 was $516,407  and $70,000, respectively.

 

Recently Issued Accounting Pronouncements

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 is amended by ASU 2018-01, ASU2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01, which FASB issued in January 2018, July 2018, July 2018, December 2018 and March 2019, respectively (collectively, the amended ASU 2016-02). The amended ASU 2016-02 requires lessees to recognize on the balance sheet a right-of-use asset, representing its right to use the underlying asset for the lease term, and a lease liability for all leases with terms greater than 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from current GAAP. The amended ASU 2016-02 retains a distinction between finance leases (i.e. capital leases under current GAAP) and operating leases. The classification criteria for distinguishing between finance leases and operating leases will be substantially similar to the classification criteria for distinguishing between capital leases and operating leases under current GAAP. The amended ASU 2016-02 also requires qualitative and quantitative disclosures designed to assess the amount, timing, and uncertainty of cash flows arising from leases. A modified retrospective transition approach is permitted to be used when an entity adopts the amended ASU 2016-02, which includes a number of optional practical expedients that entities may elect to apply.

 

We have no assets and or leases and do not believe we will be impacted in the foreseeable future by the newly adopted accounting standard(s) mentioned above.

 

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

  

Note 3 - Going Concern

 

The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

 

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.

 

The Company has not established enough sources of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to capital. There is no assurance that management’s plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

 

11

 

 

Note 4 - Income Taxes

 

The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the period presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not. As of May31, 2022, the Company has incurred a net loss of approximately $3,121,510 which resulted in a net operating loss for income tax purposes.  The loss results in a deferred tax asset of approximately $655,517 at the effective statutory rate of 21%. The deferred tax asset has been offset by an equal valuation allowance. Given our inception on December 1, 2020, and our fiscal year end of February 28, 2022, we have completed only two taxable fiscal years.

 

Note 5 - Commitments and Contingencies

 

The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies.  Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of May 31, 2022 other than the following:

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

Also on September 17, 2021, our Board of Directors unanimously agreed to approve to enter into and consummate another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.

 

On April 18, 2022, Better For You Wellness, Inc., a Nevada corporation (the “Company”), entered into a Standby Equity Commitment Agreement, dated April 11, 2022 (the “SECA”) with MacRab LLC, a Florida limited liability company (the “Investor”). The SECA provides the Company with an option to sell up to $5,000,000 worth of the Company’s common stock, par value $0.0001 (the “Common Stock”), to the Investor, in increments, over the period ending twenty-four (24) months after the date the Registration Statement (as defined below) is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. The purchase price per share, for each respective put under the SECA, is equal to 90% of the average of the two (2) lowest volume weighted average prices of the Common Stock during the six (6) trading days following the clearing date associated with the respective put under the SECA. Additionally, we issued a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock (the “Warrant”) to Investor as a commitment fee in connection with the execution of the SECA.

 

On May 26, 2022 the Company acquired Mango Moi, LLC as a wholly-owned subsidiary (See Note 1). As part of the purchase agreement, the Company entered into an employment agreement and a consulting agreement as follows:

 

Employment Agreement

 

Pursuant to the Employment Agreement, which is to be effective as of 45 days from the signing of the MIPA, the Company agreed to employ Amanda Cayemitte as the Chief Visionary Officer of Mango Moi to provide duties including normalizing the Company’s strategic-planning processes, forging new working relationships and synergies across the organization, and establishing greater transparency and accountability for those people carrying out the Company’s strategy. As compensation under the Employment Agreement, the Company agreed to pay Amanda Cayemitte  an annual salary of $65,000 payable semi-monthly on the first day and the fifteenth day of the month and subject to applicable federal, state, and local withholding.

 

12

 

 

The Employment Agreement can be terminated any time by either party by giving 30 days written notice to the other party.  If the Employment Agreement is terminated, Amanda Cayemitte will be entitled to receive compensation for:

 

one month upon completion of one full calendar year of employment with the Company;

 

two months upon completion of two full calendar years of employment with the Company, and

 

three months upon competition of two full calendar years of employment with the Company.

 

However, if Amanda Cayemitte breaches any terms of the Employment Agreement, the Company may terminate the Employment Agreement without any notice and with compensation being paid to Amanda Cayemitte only through the date of such termination. 

 

Consulting Agreement

 

Pursuant to the Consulting Agreement, the Company engaged Yapo M’be as a consultant to provide manufacturing services for Mango Moi, to begin on May 2, 2022.  As compensation under the Consulting Agreement, the Company agreed to pay Yapo M’be at the rate of $30.00 per hour, not to exceed $1,500 per month.  The Consulting Agreement can be terminated by either party upon the failure of the other to perform under the Consulting Agreement by giving ten days written notice to the non-performing party. The Consulting Agreement can also be terminated by the Company by giving ten days written notice to Yapo M’be in the event that there is a reduction of the program budget. 

 

Note 6 – Convertible Note Payable

 

On April 12, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreements”) with Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”), respectively, pursuant to which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on April 12, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.

 

Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.

 

Note 7 – Stock Purchase Warrant Liability

 

On April 18, 2022, Better For You Wellness, Inc., a Nevada corporation (the “Company”), entered into a Standby Equity Commitment Agreement, dated April 11, 2022 (the “SECA”) with MacRab LLC, a Florida limited liability company (the “Investor”). The SECA provides the Company with an option to sell up to $5,000,000 worth of the Company’s common stock, par value $0.0001 (the “Common Stock”), to the Investor, in increments, over the period ending twenty-four (24) months after the date the Registration Statement (as defined below) is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. The purchase price per share, for each respective put under the SECA, is equal to 90% of the average of the two (2) lowest volume weighted average prices of the Common Stock during the six (6) trading days following the clearing date associated with the respective put under the SECA. Additionally, we issued a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock (the “Warrant”) to Investor as a commitment fee in connection with the execution of the SECA.The Company fair valued the shares purchase warrant on the closing date at $36,366 using a Black-Scholes put option pricing model.

 

13

 

 

Note 8 - Shareholder Equity 

 

Preferred Stock

 

The authorized preferred stock of the Company consists of 200,000,000 shares with a par value of $0.0001. There were 700,000 shares issued and outstanding as of May31, 2022 and February 28, 2022.

 

During the three months ended May 31, 2021, 700,000 shares of Series A Preferred Stock were issued to CRS Consulting, LLC (“CRS”), a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody. CRS is our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock. Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock. On July 19, 2021, these shares were purchased. As of November 30, 2021, our CEO, Ian James, and Director, Stephen Letourneau, each hold 350,000 shares of Series A Preferred Stock (See Note 1).

 

Common Stock

 

The authorized common stock of the Company consists of 500,000,000 shares with a par value of $0.0001. There were 380,108,169 and 370,747,042 shares of common stock issued and outstanding as of May31, 2022 and February 28, 2022, respectively.

 

At the time of reorganization, former shareholders of Sauer Energy, Inc. became shareholders of Fast Track Solutions, Inc., representing 359,996,332 of the common shares outstanding.

 

On July 19, 2021, 250,000,000 shares of restricted Common Stock were purchased by Ohio Green Ventures, LLC from CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody (See Note 1).

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau (See Note 1).

 

On August 24, 2021, 50,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $7,000.

 

On October 11, 2021, 2,602,740 shares of Restricted Common Stock were issued to SRAX, Inc as compensation for marketing services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $468,493.

 

On October 11, 2021, 250,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $45,000.

 

On November 17, 2021, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $18,750.

 

On January 3, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $15,000.

 

14

 

 

On January 13, 2022, 549,097 shares of Restricted Common Stock were sold to five shareholders for proceeds totaling $68,000.

 

On April12, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled approximately $15,468.

 

On May 26, 2022, 11,000,000 share of Restricted Common Stock were issued to the two Sellers of Mango Moi, LLC (See Note 1). The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled approximately $550,000.

 

During the period ended May 31, 2022, a total of 325,000 shares of Restricted Common Stock were sold to two shareholders for proceeds totaling approximately $40,248.

 

Shares Cancelable

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate a “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet was a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet was for 36 months. Following the execution of the term sheet, the Company was to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH was to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital.

 

On December 2, 2021 7,048,873 shares of common stock were issued to WVH in order to honor the above agreement. However, WVH did not transfer the $250,000 purchase price of the shares to the Company and on April 12, 2022 an agreement to terminate the previous agreement was signed. On April 13, 2022 the Company forwarded a cancellation order to its transfer agent, which authorized the cancellation and return of 7,048,873 common shares previously issued to WVH. As of the date of filing, these shares have been canceled and returned to the Company.

 

Stock Options

 

During the fiscal year ended February 28, 2022, the Company granted options exercisable for up to 20,000,000 shares of Common Stock of which 2,500,000 fully vested on September 30, 2021. 17,500,000 shares vest over the next 2 years, 2,500,000 shares per quarter. The options have the exercise price of $.25 per share. These options expire 5 years after issue. The aggregate intrinsic value of these outstanding options as of May 31, 2022, was $0.

 

The Company fair valued the options on the grant dates at $2,127,565 using a Black-Scholes option pricing model with the following assumptions: stock price of $.15 and $.11 per share (based on the quoted trading price on the dates of the grants). The Company is amortizing the expense over the vesting terms of each. The total stock option expense for the period ended May 31, 2022 was approximately $262,157. The total unamortized stock option expense at May 31, 2022 was approximately $1,888,285.

 

Additional Paid-In Capital 

 

During the quarterly period ended May 31, 2022, the Sellers of Mango Moi, LLC, paid prior expenses on behalf of the wholly-owned subsidiary totaling approximately $90,956. These payments are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.

 

The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totaling $6,441 during the year ended February28, 2022. During the year ended February 28, 2022, former related party Paul Moody paid expenses on behalf of the Company totaling $500.

 

15

 

 

The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totaling $1,185 during the year ended February 28, 2021.

 

The $8,126 in total payments made by the former directors are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.

 

Note 8 - Related-Party Transactions

 

Loan to Company

 

During the period ended February 28, 2022, our CEO, Ian James, paid expenses on behalf of the Company totaling $65 and shareholder, Green Ohio Ventures, LLC, paid expenses on behalf of the Company totaling $202,475.

 

During the period ended May 31, 2022, Green Ohio Ventures, LLC, paid expenses on behalf of the Company totaling approximately $165,444 and the Company made payments to Green Ohio Ventures, LLC, totaling approximately $130,759, which resulted in a net increase of the loan amount to a total of approximately $271,738.

 

These payments are considered as loans to the Company, which are noninterest-bearing, unsecured and payable on demand.

 

In addition, the Company acquired $35,000 of a loan to Mango Moi, LLC when it became a wholly-owned subsidiary of the Company. This loan was made to Mango Moi, LLC by a relative of Amanda Cayemitte, one of the sellers of the subsidiary.

 

Note 9 - Impairment Expense

 

During the period ended May 31, 2022, the Company purchased Mango Moi, LLC (“Mango Moi”) as a wholly-owned subsidiary. The sellers of Mango Moi received 11,000,000 shares of common stock with a fair market value of approximately $550,000. The Company received approximately $7,646 of Mango Moi’s assets and took on approximately $35,119 of Mango Moi’s debts. The Company posted the net value of Mango Moi’s liabilities and the fair market value of the shares issued to the sellers as an impairment expense of $577,473.

  

Note 10 - Subsequent Events

 

On June 7, 2022, Better For You Wellness, Inc. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreements”) with Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”), respectively, pursuant to which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on June 7, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on June 7, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.

 

Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.

 

16

 

 

In connection with the Purchase Agreements, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Mast Hill, pursuant to which the Company is obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the Commitment Shares and the shares of the Company’s common stock that may be issued to Mast Hill pursuant to the conversion of the Note.

 

JH Darbie & Co., Inc. (“JH Darbie”) and the Company are parties to a Finder’s Fee Agreement, signed March 15, 2020 (“Finder’s Agreement”) pursuant to which JH Darbie would introduce the Issuer to third-party investors. Pursuant to the Finder’s Agreement,  fees of approximately $22,320.00 were paid to JH Darbie. In addition, JH Darbie is to receive non-callable warrants of equal to 8% warrant coverage of the amount raised. The warrants shall entitle JH Darbie thereof to purchase common stock of the Company at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of the Issuer’s common stock on the date of the Transaction, whichever is lower (such price, the “Warrant Price”). The warrants shall be exercisable immediately after the date of issuance, shall have anti-dilutive price protection, participating registration rights, and shall expire 5 years after the date of issuance, in accordance with the Finder’s Agreement.

 

On June 18, 2022, Dr. Nicola Finley advised the Company’s board of directors that she will resign as a board member of the Company and that her resignation is effective immediately. Dr Finley also notified the board of directors of her willingness to voluntarily relinquish the compensatory options referenced in her Director Agreement dated August 29, 2021.

 

The resignation of Dr. Finley was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

On June 20, 2022, the Company’s board of directors unanimously approved the appointment of Melisse Gelula as a non-executive independent director of the Company, effective immediately.

 

On July 11, 2022, the Company entered into a Common Share Option Cancellation and Forfeiture Agreement with former Director Dr. Nicola Finley (the “Option Cancellation and Forfeiture Agreement”). Under the Option Cancellation and Forfeiture Agreement, Dr. Nicola Finley forfeited, and the Company canceled Dr. Nicola Finley’s option to purchase 4,000,000 common shares of the Company that was granted to the optionee pursuant to the Director Agreement dated as of August 29, 2021. Upon such forfeiture and cancellation, Dr. Nicola Finley has no further rights to exercise the option to purchase 4,000,000 common shares of the Company. The cancellation and forfeiture set forth in the Option Cancellation and Forfeiture Agreement shall not affect the restricted common shares granted by the Company to Dr. Nicola Finley pursuant to the Director Agreement dated as of August 29, 2021. As a payment in lieu of whatever benefits, if any, to which Dr. Nicola Finley may have been entitled to under the option to purchase 4,000,000 common shares of the Company, the Company shall pay Dr. Nicola Finley $1.00.

 

On July 19, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Ian James, the Company’s Chief Executive Officer and the Company entered into the Agreement with Mr. James as of July 21, 2022.

 

On July 19, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Stephen Letourneau, the Company’s Chief Branding Officer and the Company entered into the Agreement with Mr. Letourneau as of July 21, 2022.

 

17

 

 

ITEM 2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements

 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.”

 

These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions.

 

Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

 

Company Overview

 

Business Overview

 

We are a sustainable brands and services company headquartered in Columbus, Ohio. We are evaluating opportunities targeting six goals-based wellness categories within the rapidly growing wellness industry to create a leading global wellness conglomerate.

 

Through our dual buy and build model, we evaluate the wellness industry in the following six goals-based categories:

 

Better Health

 

Better Fitness

 

Better Nutrition

 

Better Appearance

 

Better Sleep

 

Better Mindfulness 

 

As an early-stage company, our Company generated $13,087 and $19,455 in revenue for the three months ended May 31, 2022 and 2021 respectively. Our strategy is designed to offer wellness consumers a diverse synergistic portfolio of brands and products that will allow them to live a life of intention and improve their quality of life. On May 26, 2022, our Company closed its first acquisition of the right, title and interest in, including all of the outstanding membership interests of Mango Moi, LLC, a hair and skincare business located in Chicago, Illinois. As a fledgling brand, Mango Moi, LLC lacked capital, access to capital, and other resources necessary to scale and maintain its growth trajectory. We believe that as a result of Mango Moi, LLC’s lack of resources, our Company was presented with an attractive acquisition opportunity and that our Company’s resources would allow Mango Moi, LLC to expand.

 

18

 

 

We believe wellness consumers purchase with intention and specifically seek out the brands and products that improve their quality of life. Furthermore, we believe wellness consumers pursue these six goals-based dimensions of wellness and are positioning the Company to capitalize on this demand. With skin being a human’s largest organ, we have initially prioritized skincare and haircare to help wellness consumers look and feel better with clean and natural products. We intend to expand into additional wellness categories with functional foods, beverages, supplements, and more.

 

Our management team brings deep expertise in heavily regulated industries, operating, brand identity, genetics, and services, and raising capital to the public market. We seek synergistic and complementary mergers and acquisition opportunities, implementing operational efficiencies to eliminate duplicative measures and centralize administrative operations to achieve more significant revenues and profitability. Additionally, we expect to leverage our network of retail relationships, as well as acquire and manage brands and services cultivated in the beauty and wellness industry to secure sales in major retailers in the United States and globally.

 

Our management team monitors a variety of trends and factors that follow, which could impact our operating performance.

 

As an early-stage company, the Company has relatively few transactions to date.

 

Trends and Other Factors Affecting Our Operating Performance

 

Our management team monitors various trends and factors that could impact our operating performance.

 

Revenue Strategy

 

Our revenue growth strategy follows a dual buy and build model in which we acquire brands and related infrastructure and develop brands and related infrastructure in-house. In addition to scaling the Company’s wholly-owned subsidiary, Glow Market LLC, which currently owns and operates our Better Suds soap brand, we have executed multiple non-binding letters of intent to acquire companies within the skincare sector, including a vertically-integrated skincare manufacturer and multiple brands. The closing of these respective transactions is dependent on numerous factors, including but not limited to the satisfactory completion of due diligence, capital constraints, and more. Furthermore, any of these contemplated transactions would likely have a material impact on the Company’s operating performance. On May 26, 2022, our Company closed its first acquisition of the right, title and interest in, including all of the outstanding membership interests of Mango Moi, LLC, a hair and skincare business located in Chicago, Illinois.

 

Market Opportunity

 

We aim to become a major participant in the $1.5 trillion global wellness industry. We believe our innovative wellness-related offerings converge with wellness consumer trends and demands for “Better-For-You” brands and products that can satisfy all pricing points. We expect consumer trends towards adoption of these healthier lifestyles to continue.

 

Competition 

 

We will compete with companies that operate in the plant-based and science-focused wellness market. Many of our competitors will have substantially greater financial resources, broader market presence, longer-standing relationships with distributors, retailers, and suppliers, longer operating histories, more extensive production and distribution capabilities, more robust brand recognition, more significant marketing resources, and more comprehensive product lines than us. We believe that principal competitive factors in this category include, among others, quality ingredients, wellness profile, cost, convenience, branding, and marketing.

 

19

 

 

Sales and Marketing Costs 

 

As we continue to grow our “BFYW” product portfolio, we expect to expand our sales and marketing team by adding dedicated personnel to service additional retail customers. Outside sales representatives and brokers may be added to expand our sales efforts. We further envision engaging, developing and possibly acquiring a subscription box retail operation. Marketing expenditures are expected to begin primarily online and in product fees (as we engage retail store expansion), as well as other similar in-store marketing costs. These expenses will be categorized as net deductions to revenue under GAAP instead of marketing expenses. We plan to hire a national marketing firm to implement digital video and display campaigns, connected television, social media, and search engine marketing. As we expand and grow revenue, we will build a brand management team (to support Management, who oversees all “BFYW” marketing efforts) to focus on digital marketing, social media, and other marketing functions.

 

Operating Costs 

 

Our operating costs include raw materials, labor and related benefits, manufacturing overhead, marketing, sales, distribution, shipping, and other general and administrative expenses. We attempt to manage the impact of our operating costs through fixed hourly rate agreements with legal counsel and certain consultants.

 

Fluctuations in Costs 

 

Our costs are subject to fluctuations, particularly due to changes in commodity prices, transportation costs, and our productivity efforts. If we are unable to manage cost fluctuations through pricing actions, cost savings projects, sourcing decisions, and consistent productivity improvements, it may adversely impact our gross margin, operating margin, and net earnings. Sales can also be adversely impacted following pricing actions if there is a negative impact on the consumption of our products. We strive to implement, achieve, and sustain cost improvement plans, including supply chain optimization, general overhead and workforce optimization, as well as outsourcing projects as deemed appropriate.

 

Commodities

 

In the future, our profitability could depend on our ability to anticipate and react to raw material costs, among other things. Raw materials can be sourced from various parts of the globe, and the prices of raw goods are subject to many factors beyond our control. These factors include variables in world economic conditions, political events, tariffs, trade wars or other events.

 

Acquisitions 

 

The Company follows a dual buy and build business model for growth through acquisitions and in-house development of brands. We have executed multiple non-binding letters of intent to acquire companies within the skincare sector including a vertically-integrated skincare manufacturer and multiple brands. The closing of these respective transactions is dependent on numerous factors including but not limited to satisfactory completion of due diligence, capital constraints, and more. Furthermore, any of these contemplated transactions would likely have a material impact on the Company’s operating performance.

 

Strategic Advisory Committee

 

To assist in the expansion of the Company, management sought and received unanimous consent of the Board of Directors to create and seat a Strategic Advisory Committee composed of respected industry leaders who bring relevant experience, networks, and leadership to the Company’s various initiatives.

 

20

 

 

Discussion of Financial Statement

 

As an Early-Stage Company with few transactions, the Company’s expenditures were heavily Selling, General, and Administrative (“SG&A”). The Company engaged Carter, Ledyard, & Milburn LLP and Anthony L.G., PLLC as legal counsel, to be consulted on a case-by-case basis as may be necessary for corporate legal services and securities counsel. Payroll expenses were the single largest category of expenditure of the quarter. Management expects legal costs to taper as a percentage of overall SG&A as the company grows. BF Borgers CPA PC remains the Company’s Auditor to ensure continued financial regulatory compliance. The Company’s SG&A further includes the cost of EDGAR and news release filing services, payroll of a single person, website development and publishing, professional services such as accounting, SRAX for regular updates of NOBO data for the shareholder lists for ongoing shareholder communications, Governmental filing fees including business licensing.

 

Systems and Controls

 

As an early-stage company, the Company has very few transactions to date. The Company’s Board of Directors consists of 7 members, 5 of which are non-executive independent directors. The Board of Directors’ reviews transactions, and the CEO signs off on transactions. The Company is developing revenue recognition processes and procedures for the business, including revenue streams, point of performance obligation discharged, etc., to comply with applicable State, Federal, and International Laws and Regulations.

 

Critical Accounting Policies and Estimates

 

We prepare our consolidated financial statements in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Pursuant to Note 2 – Summary of Significant Accounting Policies, the consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.

 

The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. 

 

Revenue for products is recognized when the products are delivered to the customer and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of May 31, 2022, the Company had no deferred revenues. 

 

Going Concern

 

The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

 

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.

 

The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

 

21

 

 

COVID-19

 

An outbreak of infectious respiratory illness caused by a novel coronavirus known as COVID-19 spread globally in 2020. This outbreak resulted in travel restrictions, closed international borders, enhanced health screenings at ports of entry and elsewhere, disruption of and delays in healthcare service preparation and delivery, prolonged quarantines, cancellations, supply chain disruptions, lower consumer demand, layoffs, defaults, and other significant economic impacts, as well as general concern and uncertainty.

 

The pandemic has not materially impacted our operations in 2021 nor 2022 thus far. 

 

Financial Statements and Exhibits

 

The Company has been engaged in organizational efforts and obtaining initial financing. The Company was formed as a vehicle to pursue a business combination. The Company’s business purpose is to seek the acquisition of or merger with an existing company.

 

The Company is an “emerging growth company” (“EGC”), that is exempt from certain financial disclosure and governance requirements for up to five years as defined in the Jumpstart Our Business Startups Act (the JOBS Act), that eases restrictions on the sale of securities; and increases the number of shareholders a company must have before becoming subject to the U.S. Securities and Exchange Commissions (SEC’s) reporting and disclosure rules (See Emerging Growth Companies Section Below).

 

The Company has elected February 28th as its fiscal year-end.

 

Results of Operations

 

The following table sets forth selected items in our consolidated financial data in dollar amounts and as a percentage of revenue for the period represented:

 

   First Quarter   First Quarter 
   2022   2021   2022   2021 
Revenues  $13,087   $19,455    100%   100%
Cost of Goods  $10,268   $7,230    78.46%   37.16%
Gross Profit and Gross Margin  $2,819   $12,226    21.54%   62.84%
Operating Expenses  $1,334,455   $93,692    10,196.80%   481.58%
Net (Loss) Income  $(1,337,066)  $(81,477)   -10,216.75%   418.80%
Cash flow  $(404,695)  $(30,358)   -29.47%   -37.26%

 

Revenues

 

The company generated $13,087 and $19,455 for the three-months ended May 31, 2022, and 2021 respectively, a decrease of $6,368. The decrease was due to reduced merchandise sales due to a decrease in marketing. The Company’s current business plan is to explore and evaluate various business opportunities in the plant-based food, beverage, and consumer packaged goods (“CPG”) sectors including but not limited to mergers, acquisitions, or business combination transactions.

 

Cost of Goods Sold

 

We recorded $10,268 and $7,230 for Cost of Goods Sold for the three-months ended May 31, 2022, and 2021 respectively, an increase of $3,038. The increase in Cost of Goods Sold was due to inventory purchasing.

 

22

 

 

Gross Profit and Gross Margin

 

We recorded $2,819 and $12,226 in Gross Profit for the three-months ended May 31, 2022, and 2021 respectively, a decrease of $9,407. We recorded a substantially lower Gross Profit for our three-months ended May 31, 2022, compared to the first quarter of the prior year due to a decrease in merchandise sales. The decrease was due to a decrease in merchandise sales due to a decrease in marketing.

 

Operating Expenses

 

We recorded $1,334,455 and $93,692 in Operating Expenses for the three-months ended May 31, 2022, and 2021 respectively. We incurred substantially higher Operating Expenses for our three-months ended May 31, 2022, compared to the prior year’s first quarter due to contemplated acquisition transactions, legal fees, due diligence costs, accounting, travel, and consultants. The primary reason for the increase in operating expenses is an increase of approximately $516,407 in share-based expenses, approximately $577,473 in impairment expense, and approximately $240,576 in general and administrative expenses.

 

Income Taxes

 

The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. As of May 31, 2022, the Company has incurred a net loss of approximately $3,121,510, resulting in a net operating loss for income tax purposes. The loss results in a deferred tax asset of approximately $655,517 at the effective statutory rate of 21%. The deferred tax asset has been offset by an equal valuation allowance. Given our Company’s inception date of December 1, 2020, and our fiscal year end of February 28, 2022, we have completed only two taxable fiscal years.

 

Net (Loss) Income

 

We recorded a loss of $1,373,066 and $81,477 for the three-months ended May 31, 2022, and 2021, respectively. We recorded a substantially higher net loss for our three-months ended May 31, 2022, compared to the first quarter in the prior year due to the factors discussed above.

 

Cash flow

 

For the first quarter ending May 31, 2022, and 2021, we had negative cash flows from operating activities in the amount of $404,695 and $30,358, respectively.

 

Liquidity and Capital Resources

 

Our cash balance at May 31, 2022, and 2021 was $2,695 and $2,708, respectively. We received $254,250 and $0  from the sale of shares of Common Stock for the three-months ended May 31, 2022, and 2021 respectively. We presently are largely reliant on capital contributions towards expenses from Mr. Ian James, the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors. However, we raised a total of $250,680 in net proceeds from Mast Hill, LLC in convertible debt in the three-months ended May 31, 2022.

 

Mr. Ian James has not guaranteed that he will continue to support our capital needs. Therefore, we may not have the ability to continue as a going concern. In order to implement our plan of operations for the next twelve-month period, we may require further funding. Being a start-up stage company, we have very limited operating history. After a twelve-month period, we may need additional financing but currently do not have any arrangements for such financing.

 

If we need additional cash and cannot raise it, we will either have to suspend operations until our Company raises the necessary financing or cease operations entirely. 

 

23

 

 

Corporate History

 

Better For You Wellness, Inc. (“we”, “us”, “our”, the “Company” or the “Registrant”), was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.

 

On January 28, 2021, as a result of an Application for Custodianship granted by the Eighth Judicial District Court, Clark County, Nevada, styled as “In the matter of Sauer Energy, Inc., a Nevada corporation, Case Number: A-20-826848-P”, Jeffrey DeNunzio was appointed Custodian of Sauer Energy, Inc. (the “Predecessor”).

 

On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230, and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Jeffrey DeNunzio was the sole director/officer of each constituent corporation in the Reorganization.

 

Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor, and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.

 

Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021 at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.

 

Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until trading under the new ticker symbol “FTRK” for the Company began on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.

 

On May 5, 2021, after the completion of the Reorganization, we canceled all of the stock we held in Sauer Energy, Inc. resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.

 

On July 19, 2021, Fast Track Solutions entered into a Share Purchase Agreement by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021, CRS sold 700,000 shares of the Fast Track Solutions’ Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of Fast Track Solutions; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000). The consummation of the transactions contemplated by this Share Purchase Agreement resulted in a change in control of Fast Track Solutions, with Ian James, Stephen Letourneau and GOHV becoming the largest controlling stockholders.

 

Cumulatively, Ian James and Stephen Letourneau retained a majority of the membership interests (collectively constituting approximately 84.12%) of GOVH.

 

24

 

 

On July 30, 2021, Mr. Jeffrey DeNunzio resigned as the Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer. In addition, Mr. DeNunzio resigned as Director on July 30, 2021. Mr. Ian James was also appointed as the Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors, and Mr. Stephen Letourneau was appointed Director. The resignation of Mr. DeNunzio was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

On August 18, 2021, a Certificate of Amendment to change our name to “Better For You Wellness, Inc.” was filed with the Nevada Secretary of State.

 

On August 27, 2021, Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company.

 

On September 17, 2021, we entered into “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet is a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet is for 36 months. Following the execution of the term sheet, the Company is to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH is to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital. Pursuant to the Term Sheet, WVH may not acquire, at any point, more than 4.99% of our outstanding shares of common stock.

 

On September 17, 2021, we entered into an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

On September 17, 2021, we entered into another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.

 

On September 17, 2021, Mr. David H. Deming was appointed Secretary of the Company’s Board of Directors.

 

On September 17, 2021, we engaged Carter Ledyard Milburn LLP as the Company’s legal counsel going forward, to be consulted on a case-by-case basis as may be necessary. Any future legal fees that may be incurred are to be billed hourly and may not be static. We believe legal counsel to be important to the growth of the Company going forward.

 

On September 30, 2021, we began trading under the symbol BFYW. The new CUSIP number associated with our common stock is 08771B105.

 

On October 1, 2021, our Board of Directors unanimously approved the establishment of an Audit Committee and appointed Montel Williams, David Deming, and Joseph Watson to the newly formed Audit Committee. Our Board of Directors also unanimously approved the establishment of a Compensation Committee and appointed Leslie Bumgarner, Montel Williams, and Joseph Watson to the newly formed Compensation Committee.

 

25

 

 

On November 18, 2021, Ms. Leslie Bumgarner advised the Company’s Board of Directors that she would resign as a director and Compensation Committee member of the Company effective upon December 31, 2021. The resignation of Ms. Bumgarner was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

On December 3, 2021, the Company executed an Amended and Corrected Equity Purchase Agreement (the “Equity Purchase Agreement”) with Williamsburg Venture Holdings LLC, a Nevada limited liability Company (“WVH”). The Equity Purchase Agreement provides that WVH shall purchase from the Company, upon the filing of a Current Report on Form 8-K regarding the Company ceasing to be a “shell” company and on the approval of an uplisting to the OTCQB or higher market, $250,000 of the Company’s common stock at a 15% discount to the last closing price of the Company’s Common Stock as reported by the OTC Markets Group. The Equity Purchase Agreement also provides that, upon the filing of a registration statement on Form S-1 covering all the shares sold to WVH under the Equity Purchase Agreement and related Amended and Corrected Registration Rights Agreement (the “Registration Rights Agreement”), WVH shall purchase an additional $250,000 of the Company’s Common Stock at a 15% discount to the last closing price of the Company’s Common Stock as reported by the OTC Markets Group.

 

On December 3, 2021, the Company also executed the Registration Rights Agreement with WVH. Under the terms and conditions of the Registration Rights Agreement, and to induce WVH to enter into the Equity Purchase Agreement, the Company has agreed to provide certain registration rights under the Securities Act. The Registration Rights agreement provides that the Company shall, on or before the one hundred and eightieth (180th) day after December 3, 2021, file with the SEC a prospectus supplement on effective Form S-1 covering the maximum number of Registrable Securities (as defined therein) as shall be permitted to be included thereon in accordance with applicable SEC rules, regulations and interpretations so as to permit the resale of such Registrable Securities by the WVH, including but not limited to under Rule 415 under the Securities Act at then prevailing market prices (and not fixed prices), as mutually determined by both the Company and the WVH (the “Initial Registration Statement”). The Initial Registration Statement shall register only registrable securities. The Company shall use its commercially reasonable efforts to have the Initial Registration Statement, and any amendment thereto declared effective by the SEC at the earliest possible date (in any event, within ninety (90) calendar days after the filing date of the Initial Registration Statement). The Registration Rights Agreement also provides that the Company is obligated to file additional registration statements under certain circumstances.

 

On December 6, 2021, we announced that the Company had formed a wholly-owned subsidiary, Glow Market LLC, an Ohio Limited Liability Company, to build and operate digitally-native, mission-driven brands within the clean beauty sector in multiple consumer product categories. Glow Market LLC, launched its first brand, Better Suds, an impact-driven brand that sells cruelty-free natural soap. Better Suds is committed to positively impacting the environment by removing 1 pound of plastic from the ocean for every soap sold through donations to Ocean Blue Project Inc., a 501(c)(3) organization that removes plastics from oceans and waterways. With the Company’s launch of Glow Market LLC, we ceased to be a shell company, as defined in Rule 12b-2 under the Exchange Act, and are no longer a blank-check company.

 

On December 9, 2021, we announced that the Company had submitted an application to the OTC Markets Group to up-list its common stock for trading on the OTC Markets Venture Market, or the OTCQB, and pending the completion of the application process and its acceptance by the OTC Markets Group, the Company expects that its common stock will begin trading on the OTCQB under the Company’s current ticker symbol “BFYW”.

 

On December 14, 2021, we appointed Christina Jefferson to the Board as an Independent Director, effective January 1, 2022, in order to replace Leslie Bumgarner whose resignation became effective December 31, 2021.

 

26

 

 

On December 15, 2021, we reported on a phased fundraising of up to $1,000,000 USD in a Private Placement of restricted Common Stock to investors who qualify as “accredited investors”.

 

On February 2, 2022, we received approval from OTC Markets Group to up-list our common stock for trading to the OTC Markets Venture Market, or the OTCQB, as of February 3, 2022 under the Company’s current ticker symbol “BFYW”.

 

On February 5, 2022, our Board of Directors unanimously approved the Establishment of a Strategic Advisory Committee tasked with providing acceleration, reach and guidance to further enhance the Company’s value proposition and portfolio. Our Board of Directors appointed six initial Committee Members by unanimous consent including: David King, Laurie Racine, Zhiping Zhang, Melisse Gelula, Christopher Brown, and Kate Hendrickson.

 

Also on February 5, 2022, by unanimous consent of the five non-executive independent members of our Board of Directors, David Deming was appointed Chairperson of the Company’s Audit Committee, Christina Jefferson was appointed to the Company’s Compensation Committee filling the vacancy left by former director Leslie Bumgarner, and Joseph Watson was appointed as Chairperson of the Company’s Compensation Committee.

 

On February 11, 2022, we entered into a non-binding Letter of Intent with Amanda Cayemitte, Yapo M’Be, and Mango Moi, LLC setting forth the contemplated terms for a transaction in which the Company would acquire 100% ownership interest in Mango Moi, LLC and substantially all of the property and assets of Mango Moi including without limitation inventory, formulas, packaging, intellectual property, customer lists, websites, domain names, and social media accounts.

 

On March 15, 2022, we entered into a Finder’s Fee Agreement with JH Darbie & Co., Inc. Pursuant to which JH Darbie & Co., Inc. would introduce the Issuer to third-party investors.

 

On April 12, 2022, we entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., a Delaware limited partnership, pursuant to which Mast Hill Fund, L.P. purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 bearing an original issue discount of $31,000, interest of 12% per year and a maturity date of April 12, 2023. The promissory note is convertible into shares of our common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. We have the right to prepay the promissory note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. Pursuant to the Securities Purchase Agreement, we issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock as a condition to closing. In connection with the Securities Purchase Agreement, the Company entered into a Registration Rights Agreement with Mast Hill Fund, L.P. pursuant to which we are obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the commitment shares and the shares of our common stock that may be issued to Mast Hill Fund, L.P. pursuant to the conversion of the promissory note. Pursuant to the Finder’s Fee Agreement we entered into on March 15, 2022 with JH Darbie & Co., Inc., fees of approximately $22,320.00 were paid to JH Darbie & Co., Inc. in addition to non-callable warrants expiring 5 years after the date of issuance equal to 8% warrant coverage of the amount raised, entitling JH Darbie & Co., Inc. thereof to purchase our common stock at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of our common stock on the date of the transaction, whichever is lower.

 

Also on April 12, 2022, we entered into an Agreement to Terminate Amended and Corrected Equity Purchase Agreement (the “Agreement to Terminate”) with WVH to terminate the aforementioned Equity Purchase Agreement, whereby WVH agreed to forfeit the 7,048,873 shares of our common stock that were previously issued to WVH as commitment shares pursuant to the Equity Purchase Agreement.

 

On April 15, 2022, we entered into a Placement Agent Agreement with JH Darbie & Co., Inc. pursuant to which JH Darbie would possibly participate as a sales agent in the private placement of a $5,000,000 Equity Line of Credit.

 

On April 18, 2022, we entered into a Standby Equity Commitment Agreement with MacRab LLC, a Florida limited liability company providing us with an option to sell up to $5,000,000 worth of our common stock, par value $0.0001, to MacRab LLC, in increments, over the period ending 24 months after the date that the Company’s registration statement is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. Additionally, we issued MacRab LLC a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock as a commitment fee in connection with the execution of the Standby Equity Commitment Agreement. We also entered into a Registration Rights Agreement with the Investor requiring the Company to file a registration statement providing for the registration of the common stock issuable to MacRab LLC under the Standby Equity Commitment Agreement and their common stock purchase warrant, and the subsequent resale by MacRab LLC of such common stock. Pursuant to the Placement Agent Agreement entered into on April 15, 2022 with JH Darbie & Co., Inc., the Company will pay to Darbie a fee equal to 3% of the gross proceeds raised from the sale of the securities, including all amounts placed in an escrow account or payable in the future and all amounts paid or payable upon exercise, conversion or exchange of such securities received or receivable directly by the Company. Such consideration paid in cash shall be paid directly to Darbie out of escrow, as and when such consideration is paid to the Company.

 

27

 

 

On April 29, 2022, we entered into a Membership Interest Purchase Agreement (the “MIPA”) with Amanda Cayemitte and Yapo M’be (the “Sellers”) to acquire the right, title and interest in, including all of the outstanding membership interests of Mango Moi, LLC, for the consideration and on the terms set forth in the MIPA. Additionally, in accordance with the terms of the MIPA, we entered into an Employment Agreement with Mango Moi, LLC founder Amanda Cayemitte, and a Consulting Agreement with Yapo M’be, respectively.

 

On May 26, 2022, we closed on the Membership Interest Purchase Agreement (the “MIPA”) and acquired Mango Moi, LLC with a purchase price of $597,726.57 worth of shares of the Company’s common stock, which consisted of 11,000,000 shares of common stock, with 5,720,000 shares of Company Common Stock issued to Amanda Cayemitte and 5,280,000 shares of Company Common Stock issued to Yapo M’be. In accordance with the terms of the MIPA, we entered into an Employment Agreement with Mango Moi, LLC founder Amanda Cayemitte, and a Consulting Agreement with Yapo M’be, respectively.

 

On June 7, 2022, we entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., a Delaware limited partnership, pursuant to which Mast Hill Fund, L.P. purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 bearing an original issue discount of $31,000, interest of 12% per year and a maturity date of June 7, 2023. The promissory note is convertible into shares of our common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. We have the right to prepay the promissory note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. Pursuant to the Securities Purchase Agreement, we issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock as a condition to closing. In connection with the Securities Purchase Agreement, the Company entered into a Registration Rights Agreement with Mast Hill Fund, L.P. pursuant to which we are obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the commitment shares and the shares of our common stock that may be issued to Mast Hill Fund, L.P. pursuant to the conversion of the promissory note. Pursuant to the Finder’s Fee Agreement we entered into on March 15, 2022 with JH Darbie & Co., Inc., fees of approximately $22,320.00 were paid to JH Darbie & Co., Inc. in addition to non-callable warrants expiring 5 years after the date of issuance equal to 8% warrant coverage of the amount raised, entitling JH Darbie & Co., Inc. thereof to purchase our common stock at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of our common stock on the date of the transaction, whichever is lower.

 

On June 18, 2022, Dr. Nicola Finley advised the Company’s board of directors that she will resign as a board member of the Company and that her resignation is effective immediately. Dr Finley also notified the board of directors of her willingness to voluntarily relinquish the compensatory options referenced in her Director Agreement dated August 29, 2021.

 

The resignation of Dr. Finley was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

On June 20, 2022, the Company’s board of directors unanimously approved the appointment of Melisse Gelula as a non-executive independent director of the Company, effective immediately.

 

On July 11, 2022, the Company entered into a Common Share Option Cancellation and Forfeiture Agreement with former Director Dr. Nicola Finley (the “Option Cancellation and Forfeiture Agreement”). Under the Option Cancellation and Forfeiture Agreement, Dr. Nicola Finley forfeited, and the Company canceled Dr. Nicola Finley’s option to purchase 4,000,000 common shares of the Company that was granted to the optionee pursuant to the Director Agreement dated as of August 29, 2021. Upon such forfeiture and cancellation, Dr. Nicola Finley has no further rights to exercise the option to purchase 4,000,000 common shares of the Company. The cancellation and forfeiture set forth in the Option Cancellation and Forfeiture Agreement shall not affect the restricted common shares granted by the Company to Dr. Nicola Finley pursuant to the Director Agreement dated as of August 29, 2021. As a payment in lieu of whatever benefits, if any, to which Dr. Nicola Finley may have been entitled to under the option to purchase 4,000,000 common shares of the Company, the Company shall pay Dr. Nicola Finley $1.00.

 

On July 19, 2022, the Company’s Board of Directors approved and adopted a Code of Business Conduct and Ethics and Compliance Program designed to deter wrongdoing and to promote the types of conduct by directors, executives, and employees to uphold a strong sense of ethics and integrity.

 

On July 21, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Ian James, the Company’s Chief Executive Officer and the Company entered into the Agreement with Mr. James as of July 21, 2022. Also on July 21, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Stephen Letourneau, the Company’s Chief Branding Officer and the Company entered into the Agreement with Mr. Letourneau as of July 21, 2022.

 

28

 

 

ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.

 

ITEM 4 CONTROLS AND PROCEDURES

 

Management’s Report on Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and our chief financial officer (who is acting as our principal executive officer, principal financial officer and principle accounting officer) to allow for timely decisions regarding required disclosure.

 

As of May 31, 2022, we carried out an evaluation, under the supervision of our chief executive officer, with the participation of our chief financial officer, of the effectiveness of the design and the operation of our disclosure controls and procedures. The officers concluded that the disclosure controls and procedures were not effective as of the end of the period covered by this report due to material weaknesses identified below. 

 

The matters involving internal controls and procedures that our management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were: domination of management by a single individual without adequate compensating controls, lack of a majority of outside directors on board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; inadequate segregation of duties consistent with control objectives, and lack of an audit committee. These material weaknesses were identified by our Chief Executive Officer who also serves as our Chief Financial Officer in connection with the above evaluation.

 

Inherent limitations on effectiveness of controls

 

Internal control over financial reporting has inherent limitations which include but is not limited to the use of independent professionals for advice and guidance, interpretation of existing and/or changing rules and principles, segregation of management duties, scale of organization, and personnel factors. Internal control over financial reporting is a process which involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements on a timely basis, however these inherent limitations are known features of the financial reporting process and it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal controls over financial reporting that have occurred for the fiscal quarter ended May 31, 2021, that have materially or are reasonably likely to materially affect, our internal controls over financial reporting.

 

29

 

 

PART II-OTHER INFORMATION

 

ITEM 1 LEGAL PROCEEDINGS

 

There are no legal proceedings against the Company and the Company is unaware of such proceedings contemplated against it.

 

ITEM 1A RISK FACTORS

 

As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.

 

ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3 DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4 MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5 OTHER INFORMATION

 

None.

 

ITEM 6 EXHIBITS

 

Exhibit No.

 

Description

     
31   Certification of the Company’s Principal Executive and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s report on Form 10-Q for the period ended May 31, 2021.(2)
   
32   Certification of the Company’s Principal Executive and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.(2)
     
101.INS  

Inline XBRL Instance Document.(3)

     
101.SCH  

Inline XBRL Taxonomy Extension Schema Document.(3)

     
101.CAL  

Inline XBRL Taxonomy Extension Calculation Linkbase Document.(3)

     
101.DEF  

Inline XBRL Taxonomy Extension Definition Linkbase Document.(3)

     
101.LAB  

Inline XBRL Taxonomy Extension Label Linkbase Document.(3)

     
101.PRE  

Inline XBRL Taxonomy Extension Presentation Linkbase Document.(3)

     
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

(1) Filed as an exhibit to the Company’s Form 10-12G, as filed with the SEC on March 23, 2021, and incorporated herein by this reference.
(2) Filed herewith.
(3) Users of this data are advised that, pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or Annual Report for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Exchange Act of 1934 and otherwise are not subject to liability.

 

30

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, there unto duly authorized.

 

Better For You Wellness, Inc.  
(Registrant)  
   
By: /s/ Ian James  
Name:  Ian James  
President and Chief Executive Officer  
Dated: August 9, 2022  

 

 

31

 

370747042 370747042 0.00 0.00 195652174 363657794 false --02-28 Q1 0001852707 0001852707 2022-03-01 2022-05-31 0001852707 2022-08-04 0001852707 2022-05-31 0001852707 2022-02-28 0001852707 2021-03-01 2021-05-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0001852707 bfyw:SharesCancelableMember 2022-02-28 0001852707 us-gaap:NoncontrollingInterestMember 2022-02-28 0001852707 us-gaap:RetainedEarningsMember 2022-02-28 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-03-01 2022-05-31 0001852707 bfyw:SharesCancelableMember 2022-03-01 2022-05-31 0001852707 us-gaap:NoncontrollingInterestMember 2022-03-01 2022-05-31 0001852707 us-gaap:RetainedEarningsMember 2022-03-01 2022-05-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001852707 bfyw:SharesCancelableMember 2022-05-31 0001852707 us-gaap:NoncontrollingInterestMember 2022-05-31 0001852707 us-gaap:RetainedEarningsMember 2022-05-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-02-28 0001852707 us-gaap:NoncontrollingInterestMember 2021-02-28 0001852707 us-gaap:RetainedEarningsMember 2021-02-28 0001852707 2021-02-28 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-03-01 2021-05-31 0001852707 us-gaap:NoncontrollingInterestMember 2021-03-01 2021-05-31 0001852707 us-gaap:RetainedEarningsMember 2021-03-01 2021-05-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001852707 us-gaap:NoncontrollingInterestMember 2021-05-31 0001852707 us-gaap:RetainedEarningsMember 2021-05-31 0001852707 2021-05-31 0001852707 bfyw:PredecessorsMember 2022-05-31 0001852707 bfyw:FastTrackSolutionsIncMember 2022-05-31 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-30 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:CommonStockMember 2021-07-01 2021-07-30 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember bfyw:CRSConsultingsLLCMember 2021-07-30 0001852707 bfyw:IanJamesMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:StephenLetourneauMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-07-30 0001852707 bfyw:PurchasePriceMember 2021-07-01 2021-07-30 0001852707 bfyw:PurchasePriceMember 2021-07-30 0001852707 bfyw:MRKTSGroupIncMember 2021-08-01 2021-08-24 0001852707 bfyw:PurchasePriceMember bfyw:MRKTSGroupIncMember 2021-08-24 0001852707 bfyw:BetterForYouWellnessIncMember 2021-08-01 2021-08-25 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-08-25 0001852707 2021-08-29 2021-09-01 0001852707 bfyw:MangoMoiLLCMember us-gaap:CommonStockMember 2022-04-29 0001852707 2022-04-29 0001852707 bfyw:AmandaCayemitteMember us-gaap:CommonStockMember 2022-04-29 0001852707 bfyw:YapoMbeMember us-gaap:CommonStockMember 2022-04-29 0001852707 bfyw:SRAXIncMember 2021-09-02 2021-09-17 0001852707 2022-04-18 0001852707 2022-04-01 2022-04-18 0001852707 bfyw:MastHillFundLPMember 2022-04-12 2022-04-12 0001852707 bfyw:MastHillFundLPMember 2022-04-12 0001852707 2022-04-12 0001852707 2022-04-12 2022-04-12 0001852707 bfyw:CRSConsultingLLCMember us-gaap:SeriesAPreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember 2021-11-30 0001852707 bfyw:SauerEnergyIncMember 2022-05-31 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-07-01 2021-07-19 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-23 2021-08-25 0001852707 bfyw:CRSConsultingLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:SRAXIncMember 2021-10-01 2021-10-11 0001852707 bfyw:CRSConsultingLLCMember 2021-10-01 2021-10-11 0001852707 pf0:BoardOfDirectorsChairmanMember 2021-11-01 2021-11-17 0001852707 pf0:BoardOfDirectorsChairmanMember 2021-12-25 2022-01-03 0001852707 us-gaap:MajorityShareholderMember 2022-01-01 2022-01-13 0001852707 pf0:BoardOfDirectorsChairmanMember 2022-04-01 2022-04-12 0001852707 bfyw:MangoMoiLLCMember 2022-05-01 2022-05-26 0001852707 us-gaap:MajorityShareholderMember 2022-03-01 2022-05-31 0001852707 2021-09-02 2021-09-17 0001852707 2021-09-17 0001852707 bfyw:WilliamsburgVentureHoldingsLLCMember 2021-12-02 0001852707 bfyw:WilliamsburgVentureHoldingsLLCMember 2021-12-01 2021-12-02 0001852707 2021-09-02 2021-09-30 0001852707 2021-03-01 2022-02-28 0001852707 bfyw:JeffreyDeNunzioMember 2021-03-01 2022-02-28 0001852707 bfyw:PaulMoodyMember 2021-03-01 2022-02-28 0001852707 bfyw:JeffreyDeNunzioMember 2020-03-01 2021-02-28 0001852707 bfyw:IanJamesMember 2021-03-01 2022-02-28 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-03-01 2022-02-28 0001852707 bfyw:GreenOhioVenturesLLCMember 2022-03-01 2022-05-31 0001852707 bfyw:MangoMoiLLCMember 2022-03-01 2022-05-31 0001852707 bfyw:MangoMoiLLCMember 2022-05-31 0001852707 bfyw:MangoMoisAssetsAndTookMember 2022-03-01 2022-05-31 0001852707 bfyw:MangoMoisDebtsMember 2022-03-01 2022-05-31 0001852707 bfyw:SecuritiesPurchaseAgreementMember us-gaap:SubsequentEventMember 2022-06-07 0001852707 us-gaap:SubsequentEventMember 2022-06-02 2022-06-07 0001852707 us-gaap:SubsequentEventMember 2022-06-07 0001852707 us-gaap:SubsequentEventMember 2022-07-11 0001852707 bfyw:DrNicolaFinleyMember 2022-05-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:USD compsci:item
EX-31 2 f10q0522ex31_better.htm CERTIFICATION

 

EXHIBIT 31

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Ian James, certify that:

 

1. I have reviewed this report on Form 10-Q for the quarterly period ended May 31, 2022 of Better For You Wellness, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;

 

4. The small business issuer’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the small business issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The small business owner’s other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the small business issuer’s auditors and the audit committee of the small issuer’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer’s internal control over financial reporting.

 

Date: August 9, 2022

 

  /s/ Ian James
  Ian James
  Chief Executive Officer
  (Principal Executive Officer)

 

 

 

  

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Ian James, certify that:

 

1. I have reviewed this report on Form 10-Q for the quarterly period ended May 31, 2022 of Better For You Wellness, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;

 

4. The small business issuer’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the small business issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The small business owner’s other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the small business issuer’s auditors and the audit committee of the small issuer’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer’s internal control over financial reporting.

 

Date: August 9, 2022

 

  /s/ Ian James
  Ian James
  Chief Financial Officer
  (Principal Financial Officer)

 

 

 

EX-32 3 f10q0522ex32_better.htm CERTIFICATION

 

 EXHIBIT 32

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Better For You Wellness, Inc. (the “Company”) on Form 10-Q for the quarterly period ended May 31, 2022, as filed with the Securities and Exchange Commission (the “Report”), I, Ian James, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

 

A signed original of this written statement required by Section 906 has been provided to Ian James and will be retained by Better For You Wellness, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

Date: August 9, 2022

 

  /s/ Ian James
  Ian James
  Chief Executive Officer
  (Principal Executive Officer)

 

 

 

 

  

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Better For You Wellness, Inc. (the “Company”) on Form 10-Q for the quarterly period ended May 31, 2022, as filed with the Securities and Exchange Commission (the “Report”), I, Ian James, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

 

A signed original of this written statement required by Section 906 has been provided to Ian James and will be retained by Better For You Wellness, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

Date: August 9, 2022

 

  /s/ Ian James
  Ian James
  Chief Financial Officer
  (Principal Financial Officer)

 

 

 

EX-101.SCH 4 bfyw-20220531.xsd XBRL SCHEMA FILE 001 - Statement - Consolidated Balance Sheet link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheet (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Statement of Operations link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statement of Operations (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Consolidated Statement of Changes in Stockholders’ Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Consolidated Statement of Cash Flows link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Organization and Description of Business link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Convertible Note Payable link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Stock Purchase Warrant Liability link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Shareholder Equity link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Related-Party Transactions link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Impairment Expense link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Convertible Note Payable (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Stock Purchase Warrant Liability (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Shareholder Equity (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Impairment Expense (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 5 bfyw-20220531_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 bfyw-20220531_def.xml XBRL DEFINITION FILE EX-101.LAB 7 bfyw-20220531_lab.xml XBRL LABEL FILE EX-101.PRE 8 bfyw-20220531_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document And Entity Information - shares
3 Months Ended
May 31, 2022
Aug. 04, 2022
Document Information Line Items    
Entity Registrant Name better for you wellness, Inc.  
Document Type 10-Q  
Current Fiscal Year End Date --02-28  
Entity Common Stock, Shares Outstanding   385,198,451
Amendment Flag false  
Entity Central Index Key 0001852707  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date May 31, 2022  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q1  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Shell Company false  
Entity Ex Transition Period false  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 000-56262  
Entity Incorporation, State or Country Code NV  
Entity Tax Identification Number 87-2903933  
Entity Address, Address Line One 1349 East Broad Street  
Entity Address, City or Town Columbus  
Entity Address, State or Province OH  
Entity Address, Postal Zip Code 43205  
City Area Code (614)  
Local Phone Number 368-9898  
Entity Interactive Data Current Yes  
XML 10 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Balance Sheet - USD ($)
May 31, 2022
Feb. 28, 2022
ASSETS    
Cash $ 2,695 $ 9,719
Inventory 7,037 13,106
Total Current Assets 9,732 22,825
Equipment, net depreciation 607 731
TOTAL ASSETS 10,338 23,555
CURRENT LIABILITIES    
Loans to company – related party 306,738 305,666
Convertible note payable, net accumulated interest 315,063  
Loans payable, other   5,385
Stock Warrant liability 36,366  
Other current liabilities 119 11,150
Accrued Expenses 16,217 172,933
TOTAL LIABILITIES 674,503 495,133
Stockholders’ Equity (Deficit)    
Preferred stock ($.0001 par value, 200,000,000 shares authorized; 700,000 issued and outstanding as of May 31, 2022 and February 28, 2022) 70 70
Common stock ($.0001 par value, 500,000,000 shares authorized, 380,108,169 and 370,747,042issued and outstanding as of May 31, 2022 and February 28, 2022, respectively) 38,011 37,075
Shares Cancelable (250,000)
Additional paid-in capital 2,419,264 1,485,364
Noncontrolling interest 4,358
Accumulated deficit (3,121,510) (1,748,445)
Total Stockholders’ Equity (Deficit) (664,165) (471,578)
TOTAL LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT) $ 10,338 $ 23,555
XML 11 R3.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Balance Sheet (Parentheticals) - $ / shares
May 31, 2022
Feb. 28, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 200,000,000 200,000,000
Preferred stock, shares issued 700,000 700,000
Preferred stock, shares outstanding 700,000 700,000
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 380,108,169 370,747,042
Common stock, shares outstanding 380,108,169 370,747,042
XML 12 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statement of Operations - USD ($)
3 Months Ended
May 31, 2022
May 31, 2021
Income Statement [Abstract]    
Revenue
Merchandise Sales 13,087 19,455
Cost of Goods Sold 10,268 7,230
Gross Profit 2,819 12,226
Operating Expenses:    
Selling, general and administrative expenses 240,576 23,692
Impairment expense 577,473
Share-based expense 516,407 70,000
Total operating expenses 1,334,455 93,692
Other Income    
Other income 10
Stock warrant expense (36,366)
Other expense (5,063) (21)
Total other income(expense) (41,429) (11)
Net loss $ (1,373,066) $ (81,477)
Basic and Diluted net loss per common share (in Dollars per share) $ 0 $ 0
Weighted average number of common shares outstanding - Basic and Diluted (in Shares) 363,657,794 195,652,174
XML 13 R5.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statement of Operations (Parentheticals) - $ / shares
3 Months Ended
May 31, 2022
May 31, 2021
Income Statement [Abstract]    
Basic and Diluted net loss per common share $ 0.00 $ 0.00
Weighted average number of common shares outstanding - Basic and Diluted 363,657,794 195,652,174
XML 14 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statement of Changes in Stockholders’ Equity (Deficit) - USD ($)
Common
Shares
Series A
Preferred Shares
Additional Paid-in Capital
Shares Cancelable
Noncontrolling Interest
Accumulated Deficit
Total
Balances at Feb. 28, 2021 $ 1,185   $ (57,150) $ (55,965)
Balances (in Shares) at Feb. 28, 2021          
Common shares issued after reorganization $ 36,000 (36,000)  
Common shares issued after reorganization (in Shares) 359,996,332          
Series A preferred shares issued after reorganization $ 700 69,930     70,000
Series A preferred shares issued after reorganization (in Shares) 700,000          
Expenses paid on behalf of the Company and contributed to capital 3,951   3,951
Noncontrolling interest   20,768 20,768
Net loss     (81,477) (81,477)
Balances at May. 31, 2021 $ 36,000 $ 700 39,066   20,768 (138,627) (42,723)
Balances (in Shares) at May. 31, 2021 359,996,332 700,000          
Balances at Feb. 28, 2022 $ 37,075 $ 70 1,485,364 $ (250,000) 4,358 (1,748,445) (471,578)
Balances (in Shares) at Feb. 28, 2022 370,747,042 700,000          
Common shares canceled and returned to the Company $ (705) (249,295) 250,000
Common shares canceled and returned to the Company (in Shares) (7,048,873)          
Common shares issued for shares payable $ 33 (33)  
Common shares issued for shares payable (in Shares) 325,000          
Common shares issued for services $ 509 253,742 254,250
Common shares issued for services (in Shares) 5,085,000          
Common shares issued for purchase of subsidiary $ 1,100 576,373 577,473
Common shares issued for purchase of subsidiary (in Shares) 11,000,000          
Stock option expense 262,157 262,157
Expenses paid on behalf of the Company and contributed to capital 90,956   90,956
Noncontrolling interest (4,358)
Net loss (1,373,066) (1,373,066)
Balances at May. 31, 2022 $ 38,011 $ 70 $ 2,419,264 $ (3,121,510) $ (664,165)
Balances (in Shares) at May. 31, 2022 380,108,169 700,000          
XML 15 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statement of Cash Flows - USD ($)
3 Months Ended
May 31, 2022
May 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (1,373,066) $ (81,477)
Adjustment to reconcile net loss to net cash used in operating activities:    
Common stock issued 254,250
Preferred stock issued   70,000
Impairment expense 577,473  
Warrant expense 36,366  
Stock options expense 262,157
Amortized interest 5,063  
Changes in current assets and liabilities:    
Accrued expenses (156,716) (2,630)
Notes payable (5,385) (15,039)
Stock warrant liability 89,286  
Other current liabilities (10,893) 32
Net cash used in operating activities (404,695) (30,358)
CASH FLOWS FROM FINANCING ACTIVITIES    
Convertible note payable 310,000
Noncontrolling interest (4,358) 20,768
Expenses contributed to capital 90,956 3,951
Loan to company – related party 1,072
Net cash provided by financing activities 397,671 24,719
Net change in cash (7,024) (5,640)
Beginning cash balance 9,719 8,348
Ending cash balance 2,695 2,708
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
Interest paid
Income taxes paid
XML 16 R8.htm IDEA: XBRL DOCUMENT v3.22.2
Organization and Description of Business
3 Months Ended
May 31, 2022
Organization and Description of Business [Abstract]  
Organization and Description of Business

Note 1 - Organization and Description of Business

 

Better For You Wellness, Inc. (“we,” “us,” “our”, the “Company” or the “Registrant”) was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.

 

On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Our former director, Jeffrey DeNunzio, was the sole director/officer of each constituent corporation in the Reorganization.

 

Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.

 

Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021, at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.

 

Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until the new ticker symbol “FTRK” for the Company was released into the OTC MarketPlace on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.

 

The Company believes that the Reorganization, deemed effective on May 5, 2021, was not a transaction of the type described in subparagraph (a) of Rule 145 under the Securities Act of 1933 and the consummation of the Reorganization will not be deemed to involve an “offer”, “offer to sell”, “offer for sale” or “sale” within the meaning of Section 2(3) of the Securities Act of 1933. The Reorganization was consummated without the vote or consent of the Company’s stockholders. In addition, the provisions of NRS 92A.180 did not provide a stockholder of the Company with appraisal rights in connection with the Reorganization. The Company believes that in the absence of any right of any of the Company’s stockholders to vote with respect to the Reorganization or to insist that their shares be purchased for fair value, the Reorganization could not be deemed to involve an “offer” “offer to sell”; or “sale” within the meaning of Section 2(3) of the Securities Act of 1933.”

 

On May 5, 2021, after the completion of the Holding Company Reorganization, we canceled all of the stock we held in Sauer Energy, Inc., resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.

 

Given that the former business plan and objectives of Sauer Energy, Inc. and the business plan and objectives of Fast Track Solutions, Inc. substantially differed from one another, we conducted the corporate separation with Sauer Energy, Inc. immediately after the effective time of the Reorganization in order to avoid any shareholder confusion. The former business plan of Sauer Energy, Inc. (the development and marketing of wind powered electric generators) under the leadership of its former directors, did not, in any way, represent the blank check business plan of Fast Track Solutions, Inc. at that time, and thus it is the belief of the Company that the corporate separation ameliorated shareholder confusion about our identity and/or corporate objectives. It is our belief that Sauer Energy was a shell company at the time of the Reorganization.

 

The corporate actions taken by the Company, including, but not limited to, the corporate structuring of the transactions, was deemed, in the discretion of our sole director, to be for the benefit of the corporation and its shareholders. Former shareholders of Sauer Energy, Inc. were then the shareholders of Fast Track Solutions, Inc. and had the opportunity to benefit from a business combination with another company. The Company intended to serve as a vehicle to affect an asset acquisition, merger, exchange of capital stock or other business combination with a domestic or foreign business at that time

  

After the reorganization and through July 18, 2021, CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody, was our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock.

 

On July 19, 2021, Better For You Wellness, Inc., FKA “Fast Track Solutions, Inc.”, a Nevada Corporation (the “Company”), entered into a Share Purchase Agreement (the “Agreement”) by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021 (“Closing Date”), CRS sold 700,000 shares of the Company’s Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of the Company; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000) (the “Purchase Price”). The consummation of the transactions contemplated by the Agreement resulted in a change in control of the Company, with GOHV, Ian James, and Stephen Letourneau, becoming the Company’s largest controlling stockholders having approximately 89.62% combined voting control over the Company.

 

Pursuant to the Agreement, on July 30, 2021, Mr. Jeffrey DeNunzio resigned as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Director.

 

On July 30, 2021, Mr. Ian James was appointed as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors and Mr. Stephen Letourneau was appointed as a Director.

 

On August 19, 2021, the Company filed an 8-K with the SEC to disclose an amendment to the Company’s Articles of Incorporation that the Company filed on August 18, 2021, with the Nevada Secretary of State to change its name to Better For You Wellness, Inc. Within the aforementioned 8-K, the Company disclosed that, at the time, it was pending a FINRA corporate action to affect the name change on the OTC to Better For You Wellness, Inc., and also a ticker symbol change. FINRA announced, on their September 29, 2021 daily list, that the market effective date of our name change, and ticker symbol change, will be September 30, 2021. On September 30, 2021, we will begin trading under the symbol BFYW. The new CUSIP number associated with our common stock, as of the market effective date of September 30, 2021, is 08771B105.

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided. This transaction did not result in MRKTS Group Inc. owning 5% or more of any class of securities of the issuer.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau. The aforementioned transaction(s) did not result in any individual shareholder owning 5% or more of any class of securities of the issuer. The aforementioned transaction was carried out as it was deemed by GOHV to be in the best interests of its members.

 

On August 27, 2021, Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company.

 

On September 1, 2021, we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per annum, paid in equal $250 distributions quarterly, and 200,000 shares of common stock, issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share. The Directors were officially seated September 12, 2021, after notification to shareholders. On December 14, 2021, the Company’s Board of Directors unanimously approved the appointment of Christina Jefferson to the Board as an Independent Director, effective January 1, 2022. Christina Jefferson replaced Leslie Bumgarner whose resignation, as previously announced, became effective December 31, 2021.

 

On February 3. 2022, the Company was approved by OTC Markets to up-list its common stock from the OTC Pink Sheets to the OTCQB® Venture Market (the “OTCQB”). The Company began trading of its common shares on the OTCQB as of the market open on February 3, 2022, under its same symbol, “BFYW.”

 

On February 5, 2022, the Company’s Board of Directors unanimously approved the establishment of a Strategic Advisory Committee. The Board appointed six initial members by unanimous consent including David King, Laurie Racine, Zhiping Zhang, Melisse Gelula, Christopher Brown, and Kate Hendrickson.

 

Also on February 5, 2022, by unanimous vote of the Company’s Board of Directors’ five non-executive Independent Directors, David Deming was appointed Chairperson of the Company’s Audit Committee, which follows the Board’s October 1, 2021, unanimous consent to establish the Audit Committee. The Audit Committee currently consists of three non-executive Independent Directors, including Montel Williams, Joseph Watson, and David Deming. Also, by unanimous vote of the Board’s five non-executive Independent Directors, Christina Jefferson was appointed to the Company’s Compensation Committee, filling the vacancy left by former Director Leslie Bumgarner. This action follows the Board’s October 1, 2021, unanimous consent to establish the Compensation Committee. The Compensation Committee currently consists of Independent Directors, Christina Jefferson, Montel Williams, and Joseph Watson. Additionally, the Board’s five non-executive Independent Directors unanimously appointed Joseph Watson as Chairperson of the Compensation Committee.

 

The Company’s current business plan is to explore and evaluate various opportunities in the plant-based food and beverage and consumer packaged goods sectors, including but not limited to, mergers, acquisitions, or business combination transactions, after which the Company would cease to be a “shell” or “blank check” company. The Company’s principal business objective for the next 12 months and beyond will be to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings.

 

On November 15, 2021, the Company’s wholly owned subsidiary, Glow Market, LLC was formed in the State of Ohio. Subsequently, Glow Market, LLC launched its first brand, Better Suds, an online retailer of specialty all-natural, cruelty-free, gluten-free and chemical-free soaps. Better Suds commenced operations in December 2021.

 

On April 29, 2022 the Company entered into a Membership Interest Purchase Agreement (the “MIPA”) with Amanda Cayemitte and Yapo M’be (referred to together as the “Sellers”) to acquire the right, title and interest in, including all of the outstanding membership interests (referred to together as the “MM Interests”) of Mango Moi, LLC (“Mango Moi”).

 

Mango Moi is a hair and skincare business located in Chicago, Illinois. Pursuant to the MIPA, in exchange for the MM Interests, the Company agreed to pay the Sellers a purchase price consisting of shares of the Company’s common stock, par value $0.0001 per share which consists of 11,000,000 shares of common stock (the “Company Common Stock”), with a fair market value of approximately $550,000, with 5,720,000 shares of Company Common Stock issued to Amanda Cayemitte and 5,280,000 shares of Company Common Stock issued to Yapo M’be (referred to together herein as the “Purchase Price”). Additionally, pursuant to the terms of the MIPA, the Company agreed to enter into an Employment Agreement with Mango Moi founder Amanda Cayemitte (the “Employment Agreement”), and a Consulting Agreement with Yapo M’be  (the “Consulting Agreement”), respectively, as disclosed by the Company on its Current Report on Form 8-K filed with the SEC on May 2, 2022.

 

The MIPA closed (the “Closing”) on May 26, 2022, on which date the Company paid the Sellers the Purchase Price by issuing the Company Common Stock to the Sellers and the Sellers transferred the MM Interests to the Company, and on which date Mango Moi became a wholly owned subsidiary of the Company. At the Closing the Company entered into the Employment Agreement with Amanda Cayemitte and the Consulting Agreement with Yapo M’be.

 

The Company intends to optimize Mango Moi’s product formulae and packaging, as well as secure new manufacturing relationships to scale production capacity. Additionally, the Company plans to expand Mango Moi’s product offerings to include additional products and product bundles. Furthermore, the Company intends to grow sales through direct-to-consumer marketing efforts, subscription box sales, and pursuing wholesale sales relationships. 

 

The Company’s main office is located at 1349 East Broad Street, Columbus OH 43205.

 

The Company has elected February 28th as its year end.

XML 17 R9.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies
3 Months Ended
May 31, 2022
Organization and Description of Business [Abstract]  
Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Glow Markets, LLC and Mango Moi, LLC. All significant intercompany accounts and transactions have been eliminated.

 

Basis of Presentation

 

This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at May 31, 2022 and February 28, 2022 were $2,695 and $9,719 respectively. 

 

Revenue recognition

 

The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

 

Revenue for products is recognized when the products are delivered to the customer and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of May 31, 2022, the Company had no deferred revenues. 

 

Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.”  Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs.  A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at May 31, 2022.

 

Basic Earnings (Loss) Per Share

 

The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company does not have any potentially dilutive instruments as of May 31, 2022 and, thus, anti-dilution issues are not applicable.

 

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

 

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.  

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.

 

Related Parties

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

Share-Based Compensation

 

ASC 718, “Compensation – Stock Compensation”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.”  Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable:  (a) the goods or services received; or (b) the equity instruments issued.  The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.  

 

The Company had no stock-based compensation plans as of May 31, 2022 and February 28, 2022.

 

The Company’s stock-based compensation for the period ended May 31, 2022 and May 31, 2021 was $516,407  and $70,000, respectively.

 

Recently Issued Accounting Pronouncements

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 is amended by ASU 2018-01, ASU2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01, which FASB issued in January 2018, July 2018, July 2018, December 2018 and March 2019, respectively (collectively, the amended ASU 2016-02). The amended ASU 2016-02 requires lessees to recognize on the balance sheet a right-of-use asset, representing its right to use the underlying asset for the lease term, and a lease liability for all leases with terms greater than 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from current GAAP. The amended ASU 2016-02 retains a distinction between finance leases (i.e. capital leases under current GAAP) and operating leases. The classification criteria for distinguishing between finance leases and operating leases will be substantially similar to the classification criteria for distinguishing between capital leases and operating leases under current GAAP. The amended ASU 2016-02 also requires qualitative and quantitative disclosures designed to assess the amount, timing, and uncertainty of cash flows arising from leases. A modified retrospective transition approach is permitted to be used when an entity adopts the amended ASU 2016-02, which includes a number of optional practical expedients that entities may elect to apply.

 

We have no assets and or leases and do not believe we will be impacted in the foreseeable future by the newly adopted accounting standard(s) mentioned above.

 

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

XML 18 R10.htm IDEA: XBRL DOCUMENT v3.22.2
Going Concern
3 Months Ended
May 31, 2022
Going Concern [Abstract]  
Going Concern

Note 3 - Going Concern

 

The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

 

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.

 

The Company has not established enough sources of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to capital. There is no assurance that management’s plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

XML 19 R11.htm IDEA: XBRL DOCUMENT v3.22.2
Income Taxes
3 Months Ended
May 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes

Note 4 - Income Taxes

 

The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the period presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not. As of May31, 2022, the Company has incurred a net loss of approximately $3,121,510 which resulted in a net operating loss for income tax purposes.  The loss results in a deferred tax asset of approximately $655,517 at the effective statutory rate of 21%. The deferred tax asset has been offset by an equal valuation allowance. Given our inception on December 1, 2020, and our fiscal year end of February 28, 2022, we have completed only two taxable fiscal years.

XML 20 R12.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies
3 Months Ended
May 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 5 - Commitments and Contingencies

 

The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies.  Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of May 31, 2022 other than the following:

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

Also on September 17, 2021, our Board of Directors unanimously agreed to approve to enter into and consummate another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.

 

On April 18, 2022, Better For You Wellness, Inc., a Nevada corporation (the “Company”), entered into a Standby Equity Commitment Agreement, dated April 11, 2022 (the “SECA”) with MacRab LLC, a Florida limited liability company (the “Investor”). The SECA provides the Company with an option to sell up to $5,000,000 worth of the Company’s common stock, par value $0.0001 (the “Common Stock”), to the Investor, in increments, over the period ending twenty-four (24) months after the date the Registration Statement (as defined below) is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. The purchase price per share, for each respective put under the SECA, is equal to 90% of the average of the two (2) lowest volume weighted average prices of the Common Stock during the six (6) trading days following the clearing date associated with the respective put under the SECA. Additionally, we issued a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock (the “Warrant”) to Investor as a commitment fee in connection with the execution of the SECA.

 

On May 26, 2022 the Company acquired Mango Moi, LLC as a wholly-owned subsidiary (See Note 1). As part of the purchase agreement, the Company entered into an employment agreement and a consulting agreement as follows:

 

Employment Agreement

 

Pursuant to the Employment Agreement, which is to be effective as of 45 days from the signing of the MIPA, the Company agreed to employ Amanda Cayemitte as the Chief Visionary Officer of Mango Moi to provide duties including normalizing the Company’s strategic-planning processes, forging new working relationships and synergies across the organization, and establishing greater transparency and accountability for those people carrying out the Company’s strategy. As compensation under the Employment Agreement, the Company agreed to pay Amanda Cayemitte  an annual salary of $65,000 payable semi-monthly on the first day and the fifteenth day of the month and subject to applicable federal, state, and local withholding.

 

The Employment Agreement can be terminated any time by either party by giving 30 days written notice to the other party.  If the Employment Agreement is terminated, Amanda Cayemitte will be entitled to receive compensation for:

 

one month upon completion of one full calendar year of employment with the Company;

 

two months upon completion of two full calendar years of employment with the Company, and

 

three months upon competition of two full calendar years of employment with the Company.

 

However, if Amanda Cayemitte breaches any terms of the Employment Agreement, the Company may terminate the Employment Agreement without any notice and with compensation being paid to Amanda Cayemitte only through the date of such termination. 

 

Consulting Agreement

 

Pursuant to the Consulting Agreement, the Company engaged Yapo M’be as a consultant to provide manufacturing services for Mango Moi, to begin on May 2, 2022.  As compensation under the Consulting Agreement, the Company agreed to pay Yapo M’be at the rate of $30.00 per hour, not to exceed $1,500 per month.  The Consulting Agreement can be terminated by either party upon the failure of the other to perform under the Consulting Agreement by giving ten days written notice to the non-performing party. The Consulting Agreement can also be terminated by the Company by giving ten days written notice to Yapo M’be in the event that there is a reduction of the program budget. 

XML 21 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Convertible Note Payable
3 Months Ended
May 31, 2022
Convertible Note Payable Disclosure [Abstract]  
Convertible Note Payable

Note 6 – Convertible Note Payable

 

On April 12, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreements”) with Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”), respectively, pursuant to which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on April 12, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.

 

Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.

XML 22 R14.htm IDEA: XBRL DOCUMENT v3.22.2
Stock Purchase Warrant Liability
3 Months Ended
May 31, 2022
Stock Purchase Warrant Liability [Abstract]  
Stock Purchase Warrant Liability

Note 7 – Stock Purchase Warrant Liability

 

On April 18, 2022, Better For You Wellness, Inc., a Nevada corporation (the “Company”), entered into a Standby Equity Commitment Agreement, dated April 11, 2022 (the “SECA”) with MacRab LLC, a Florida limited liability company (the “Investor”). The SECA provides the Company with an option to sell up to $5,000,000 worth of the Company’s common stock, par value $0.0001 (the “Common Stock”), to the Investor, in increments, over the period ending twenty-four (24) months after the date the Registration Statement (as defined below) is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. The purchase price per share, for each respective put under the SECA, is equal to 90% of the average of the two (2) lowest volume weighted average prices of the Common Stock during the six (6) trading days following the clearing date associated with the respective put under the SECA. Additionally, we issued a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock (the “Warrant”) to Investor as a commitment fee in connection with the execution of the SECA.The Company fair valued the shares purchase warrant on the closing date at $36,366 using a Black-Scholes put option pricing model.

XML 23 R15.htm IDEA: XBRL DOCUMENT v3.22.2
Shareholder Equity
3 Months Ended
May 31, 2022
Shareholder Equity [Abstract]  
Shareholder Equity

Note 8 - Shareholder Equity 

 

Preferred Stock

 

The authorized preferred stock of the Company consists of 200,000,000 shares with a par value of $0.0001. There were 700,000 shares issued and outstanding as of May31, 2022 and February 28, 2022.

 

During the three months ended May 31, 2021, 700,000 shares of Series A Preferred Stock were issued to CRS Consulting, LLC (“CRS”), a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody. CRS is our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock. Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock. On July 19, 2021, these shares were purchased. As of November 30, 2021, our CEO, Ian James, and Director, Stephen Letourneau, each hold 350,000 shares of Series A Preferred Stock (See Note 1).

 

Common Stock

 

The authorized common stock of the Company consists of 500,000,000 shares with a par value of $0.0001. There were 380,108,169 and 370,747,042 shares of common stock issued and outstanding as of May31, 2022 and February 28, 2022, respectively.

 

At the time of reorganization, former shareholders of Sauer Energy, Inc. became shareholders of Fast Track Solutions, Inc., representing 359,996,332 of the common shares outstanding.

 

On July 19, 2021, 250,000,000 shares of restricted Common Stock were purchased by Ohio Green Ventures, LLC from CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody (See Note 1).

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau (See Note 1).

 

On August 24, 2021, 50,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $7,000.

 

On October 11, 2021, 2,602,740 shares of Restricted Common Stock were issued to SRAX, Inc as compensation for marketing services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $468,493.

 

On October 11, 2021, 250,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $45,000.

 

On November 17, 2021, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $18,750.

 

On January 3, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $15,000.

 

On January 13, 2022, 549,097 shares of Restricted Common Stock were sold to five shareholders for proceeds totaling $68,000.

 

On April12, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled approximately $15,468.

 

On May 26, 2022, 11,000,000 share of Restricted Common Stock were issued to the two Sellers of Mango Moi, LLC (See Note 1). The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled approximately $550,000.

 

During the period ended May 31, 2022, a total of 325,000 shares of Restricted Common Stock were sold to two shareholders for proceeds totaling approximately $40,248.

 

Shares Cancelable

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate a “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet was a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet was for 36 months. Following the execution of the term sheet, the Company was to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH was to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital.

 

On December 2, 2021 7,048,873 shares of common stock were issued to WVH in order to honor the above agreement. However, WVH did not transfer the $250,000 purchase price of the shares to the Company and on April 12, 2022 an agreement to terminate the previous agreement was signed. On April 13, 2022 the Company forwarded a cancellation order to its transfer agent, which authorized the cancellation and return of 7,048,873 common shares previously issued to WVH. As of the date of filing, these shares have been canceled and returned to the Company.

 

Stock Options

 

During the fiscal year ended February 28, 2022, the Company granted options exercisable for up to 20,000,000 shares of Common Stock of which 2,500,000 fully vested on September 30, 2021. 17,500,000 shares vest over the next 2 years, 2,500,000 shares per quarter. The options have the exercise price of $.25 per share. These options expire 5 years after issue. The aggregate intrinsic value of these outstanding options as of May 31, 2022, was $0.

 

The Company fair valued the options on the grant dates at $2,127,565 using a Black-Scholes option pricing model with the following assumptions: stock price of $.15 and $.11 per share (based on the quoted trading price on the dates of the grants). The Company is amortizing the expense over the vesting terms of each. The total stock option expense for the period ended May 31, 2022 was approximately $262,157. The total unamortized stock option expense at May 31, 2022 was approximately $1,888,285.

 

Additional Paid-In Capital 

 

During the quarterly period ended May 31, 2022, the Sellers of Mango Moi, LLC, paid prior expenses on behalf of the wholly-owned subsidiary totaling approximately $90,956. These payments are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.

 

The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totaling $6,441 during the year ended February28, 2022. During the year ended February 28, 2022, former related party Paul Moody paid expenses on behalf of the Company totaling $500.

 

The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totaling $1,185 during the year ended February 28, 2021.

 

The $8,126 in total payments made by the former directors are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.

XML 24 R16.htm IDEA: XBRL DOCUMENT v3.22.2
Related-Party Transactions
3 Months Ended
May 31, 2022
Related-Party Transactions [Abstract]  
Related-Party Transactions

Note 8 - Related-Party Transactions

 

Loan to Company

 

During the period ended February 28, 2022, our CEO, Ian James, paid expenses on behalf of the Company totaling $65 and shareholder, Green Ohio Ventures, LLC, paid expenses on behalf of the Company totaling $202,475.

 

During the period ended May 31, 2022, Green Ohio Ventures, LLC, paid expenses on behalf of the Company totaling approximately $165,444 and the Company made payments to Green Ohio Ventures, LLC, totaling approximately $130,759, which resulted in a net increase of the loan amount to a total of approximately $271,738.

 

These payments are considered as loans to the Company, which are noninterest-bearing, unsecured and payable on demand.

 

In addition, the Company acquired $35,000 of a loan to Mango Moi, LLC when it became a wholly-owned subsidiary of the Company. This loan was made to Mango Moi, LLC by a relative of Amanda Cayemitte, one of the sellers of the subsidiary.

XML 25 R17.htm IDEA: XBRL DOCUMENT v3.22.2
Impairment Expense
3 Months Ended
May 31, 2022
Impairment Expense [Abstract]  
Impairment Expense

Note 9 - Impairment Expense

 

During the period ended May 31, 2022, the Company purchased Mango Moi, LLC (“Mango Moi”) as a wholly-owned subsidiary. The sellers of Mango Moi received 11,000,000 shares of common stock with a fair market value of approximately $550,000. The Company received approximately $7,646 of Mango Moi’s assets and took on approximately $35,119 of Mango Moi’s debts. The Company posted the net value of Mango Moi’s liabilities and the fair market value of the shares issued to the sellers as an impairment expense of $577,473.

XML 26 R18.htm IDEA: XBRL DOCUMENT v3.22.2
Subsequent Events
3 Months Ended
May 31, 2022
Subsequent Events [Abstract]  
Subsequent Events

Note 10 - Subsequent Events

 

On June 7, 2022, Better For You Wellness, Inc. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreements”) with Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”), respectively, pursuant to which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on June 7, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on June 7, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.

 

Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.

 

In connection with the Purchase Agreements, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Mast Hill, pursuant to which the Company is obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the Commitment Shares and the shares of the Company’s common stock that may be issued to Mast Hill pursuant to the conversion of the Note.

 

JH Darbie & Co., Inc. (“JH Darbie”) and the Company are parties to a Finder’s Fee Agreement, signed March 15, 2020 (“Finder’s Agreement”) pursuant to which JH Darbie would introduce the Issuer to third-party investors. Pursuant to the Finder’s Agreement,  fees of approximately $22,320.00 were paid to JH Darbie. In addition, JH Darbie is to receive non-callable warrants of equal to 8% warrant coverage of the amount raised. The warrants shall entitle JH Darbie thereof to purchase common stock of the Company at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of the Issuer’s common stock on the date of the Transaction, whichever is lower (such price, the “Warrant Price”). The warrants shall be exercisable immediately after the date of issuance, shall have anti-dilutive price protection, participating registration rights, and shall expire 5 years after the date of issuance, in accordance with the Finder’s Agreement.

 

On June 18, 2022, Dr. Nicola Finley advised the Company’s board of directors that she will resign as a board member of the Company and that her resignation is effective immediately. Dr Finley also notified the board of directors of her willingness to voluntarily relinquish the compensatory options referenced in her Director Agreement dated August 29, 2021.

 

The resignation of Dr. Finley was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

On June 20, 2022, the Company’s board of directors unanimously approved the appointment of Melisse Gelula as a non-executive independent director of the Company, effective immediately.

 

On July 11, 2022, the Company entered into a Common Share Option Cancellation and Forfeiture Agreement with former Director Dr. Nicola Finley (the “Option Cancellation and Forfeiture Agreement”). Under the Option Cancellation and Forfeiture Agreement, Dr. Nicola Finley forfeited, and the Company canceled Dr. Nicola Finley’s option to purchase 4,000,000 common shares of the Company that was granted to the optionee pursuant to the Director Agreement dated as of August 29, 2021. Upon such forfeiture and cancellation, Dr. Nicola Finley has no further rights to exercise the option to purchase 4,000,000 common shares of the Company. The cancellation and forfeiture set forth in the Option Cancellation and Forfeiture Agreement shall not affect the restricted common shares granted by the Company to Dr. Nicola Finley pursuant to the Director Agreement dated as of August 29, 2021. As a payment in lieu of whatever benefits, if any, to which Dr. Nicola Finley may have been entitled to under the option to purchase 4,000,000 common shares of the Company, the Company shall pay Dr. Nicola Finley $1.00.

 

On July 19, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Ian James, the Company’s Chief Executive Officer and the Company entered into the Agreement with Mr. James as of July 21, 2022.

 

On July 19, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Stephen Letourneau, the Company’s Chief Branding Officer and the Company entered into the Agreement with Mr. Letourneau as of July 21, 2022.

XML 27 R19.htm IDEA: XBRL DOCUMENT v3.22.2
Accounting Policies, by Policy (Policies)
3 Months Ended
May 31, 2022
Organization and Description of Business [Abstract]  
Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Glow Markets, LLC and Mango Moi, LLC. All significant intercompany accounts and transactions have been eliminated.

 

Basis of Presentation

Basis of Presentation

 

This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.

 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at May 31, 2022 and February 28, 2022 were $2,695 and $9,719 respectively. 

 

Revenue Recognition

Revenue recognition

 

The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

 

Revenue for products is recognized when the products are delivered to the customer and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of May 31, 2022, the Company had no deferred revenues. 

 

Income Taxes

Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.”  Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs.  A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at May 31, 2022.

 

Basic Earnings (Loss) Per Share

Basic Earnings (Loss) Per Share

 

The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company does not have any potentially dilutive instruments as of May 31, 2022 and, thus, anti-dilution issues are not applicable.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

 

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.  

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.

 

Related Parties

Related Parties

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

Share-Based Compensation

Share-Based Compensation

 

ASC 718, “Compensation – Stock Compensation”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.”  Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable:  (a) the goods or services received; or (b) the equity instruments issued.  The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.  

 

The Company had no stock-based compensation plans as of May 31, 2022 and February 28, 2022.

 

The Company’s stock-based compensation for the period ended May 31, 2022 and May 31, 2021 was $516,407  and $70,000, respectively.

 

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 is amended by ASU 2018-01, ASU2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01, which FASB issued in January 2018, July 2018, July 2018, December 2018 and March 2019, respectively (collectively, the amended ASU 2016-02). The amended ASU 2016-02 requires lessees to recognize on the balance sheet a right-of-use asset, representing its right to use the underlying asset for the lease term, and a lease liability for all leases with terms greater than 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from current GAAP. The amended ASU 2016-02 retains a distinction between finance leases (i.e. capital leases under current GAAP) and operating leases. The classification criteria for distinguishing between finance leases and operating leases will be substantially similar to the classification criteria for distinguishing between capital leases and operating leases under current GAAP. The amended ASU 2016-02 also requires qualitative and quantitative disclosures designed to assess the amount, timing, and uncertainty of cash flows arising from leases. A modified retrospective transition approach is permitted to be used when an entity adopts the amended ASU 2016-02, which includes a number of optional practical expedients that entities may elect to apply.

 

We have no assets and or leases and do not believe we will be impacted in the foreseeable future by the newly adopted accounting standard(s) mentioned above.

 

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

XML 28 R20.htm IDEA: XBRL DOCUMENT v3.22.2
Organization and Description of Business (Details) - USD ($)
1 Months Ended
Sep. 01, 2021
Aug. 25, 2021
Aug. 24, 2021
Jul. 30, 2021
Jul. 18, 2021
May 31, 2022
Apr. 29, 2022
Feb. 28, 2022
Organization and Description of Business (Details) [Line Items]                
Independent director agreements, description we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per annum, paid in equal $250 distributions quarterly, and 200,000 shares of common stock, issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share.              
Common stock, par value (in Dollars per share)           $ 0.0001   $ 0.0001
Shares of common stock           500,000,000   500,000,000
Fair market value (in Dollars)             $ 550,000  
Common stock, shares issued           380,108,169   370,747,042
Fast Track Solutions, Inc. [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of common stock           1,000    
Series A Preferred Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of restricted common stock         250,000,000      
Series of Individually Immaterial Business Acquisitions [Member]                
Organization and Description of Business (Details) [Line Items]                
Owning, percentage   5.00%            
Purchase Price [Member]                
Organization and Description of Business (Details) [Line Items]                
Voting percentage       89.62%        
Paid consideration (in Dollars)       $ 335,000        
Predecessor [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of common stock           1,000    
CRS Consulting, LLC [Member] | Common Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of common stock       250,000,000        
CRS Consulting, LLC [Member] | Series A Preferred Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Shareholder owning preferred stock         700,000      
Sale of shares       700,000        
CRS Consulting, LLC [Member] | Series of Individually Immaterial Business Acquisitions [Member]                
Organization and Description of Business (Details) [Line Items]                
Voting percentage       89.62%        
Ian James [Member] | Series A Preferred Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Transfer of shares       350,000        
Stephen Letourneau [Member] | Series A Preferred Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Transfer of shares       350,000        
Green Ohio Ventures, LLC [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of common stock       250,000,000        
MRKTS Group Inc [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of restricted common stock     17,963,817          
MRKTS Group Inc [Member] | Purchase Price [Member]                
Organization and Description of Business (Details) [Line Items]                
Owning, percentage     5.00%          
Better for You Wellness, Inc. [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of restricted common stock   24,137,499            
Mango Moi, LLC [Member] | Common Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Common stock, par value (in Dollars per share)             $ 0.0001  
Shares of common stock             11,000,000  
Amanda Cayemitte [Member] | Common Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Common stock, shares issued             5,720,000  
Yapo M’be [Member] | Common Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Common stock, shares issued             5,280,000  
XML 29 R21.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Details) - USD ($)
May 31, 2022
Feb. 28, 2022
May 31, 2021
Organization and Description of Business [Abstract]      
Cash and cash equivalents $ 2,695 $ 9,719  
Stock-based compensation $ 516,407   $ 70,000
XML 30 R22.htm IDEA: XBRL DOCUMENT v3.22.2
Income Taxes (Details)
3 Months Ended
May 31, 2022
USD ($)
Income Tax Disclosure [Abstract]  
Net loss $ 3,121,510
Deferred tax asset $ 655,517
Effective statutory rate 21.00%
XML 31 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies (Details)
1 Months Ended 3 Months Ended
Apr. 18, 2022
$ / shares
$ / item
shares
Sep. 17, 2021
USD ($)
May 31, 2022
USD ($)
Commitments and Contingencies (Details) [Line Items]      
Amount paid     $ 22,320
Option to sell amount (in Dollars per Item) | $ / item 5,000,000    
Common stock, par value (in Dollars per share) | $ / shares $ 0.0001    
Purchase price per share equal to percentage 90.00%    
Common stock purchase warrant for purchase (in Shares) | shares 1,785,714    
Annual salary of payable     $ 65,000
Consulting agreement, description     Pursuant to the Consulting Agreement, the Company engaged Yapo M’be as a consultant to provide manufacturing services for Mango Moi, to begin on May 2, 2022.  As compensation under the Consulting Agreement, the Company agreed to pay Yapo M’be at the rate of $30.00 per hour, not to exceed $1,500 per month.
SRAX [Member]      
Commitments and Contingencies (Details) [Line Items]      
Amount paid   $ 20,000  
XML 32 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Convertible Note Payable (Details)
Apr. 12, 2022
USD ($)
$ / shares
shares
Convertible Note Payable (Details) [Line Items]  
Discount amount $ 31,000
Interest rate 12.00%
Maturity date Apr. 12, 2023
Common stock conversion price per share (in Dollars per share) | $ / shares $ 0.037
Mast Hill Fund, L.P., [Member]  
Convertible Note Payable (Details) [Line Items]  
Principal amount $ 310,000
Purchase price $ 279,000
Commitment shares (in Shares) | shares 4,960,000
XML 33 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Stock Purchase Warrant Liability (Details)
1 Months Ended
Apr. 18, 2022
Stock Purchase Warrant Liability [Abstract]  
Stock purchase warrant liability description Better For You Wellness, Inc., a Nevada corporation (the “Company”), entered into a Standby Equity Commitment Agreement, dated April 11, 2022 (the “SECA”) with MacRab LLC, a Florida limited liability company (the “Investor”). The SECA provides the Company with an option to sell up to $5,000,000 worth of the Company’s common stock, par value $0.0001 (the “Common Stock”), to the Investor, in increments, over the period ending twenty-four (24) months after the date the Registration Statement (as defined below) is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. The purchase price per share, for each respective put under the SECA, is equal to 90% of the average of the two (2) lowest volume weighted average prices of the Common Stock during the six (6) trading days following the clearing date associated with the respective put under the SECA. Additionally, we issued a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock (the “Warrant”) to Investor as a commitment fee in connection with the execution of the SECA.The Company fair valued the shares purchase warrant on the closing date at $36,366 using a Black-Scholes put option pricing model.
XML 34 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Shareholder Equity (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Apr. 12, 2022
Jan. 13, 2022
Jan. 03, 2022
Dec. 02, 2021
Oct. 11, 2021
Aug. 25, 2021
May 26, 2022
Nov. 17, 2021
Sep. 30, 2021
Sep. 17, 2021
Aug. 24, 2021
Jul. 19, 2021
May 31, 2022
May 31, 2021
Feb. 28, 2022
Feb. 28, 2021
Nov. 30, 2021
Shareholder Equity (Details) [Line Items]                                  
Preferred stock, shares authorized                         200,000,000   200,000,000    
Preferred stock, par value (in Dollars per share)                         $ 0.0001   $ 0.0001    
Preferred stock, shares issued                         700,000   700,000    
Preferred stock, shares outstanding                         700,000   700,000    
Preferred stock, voting rights                         Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock.        
Common stock, shares authorized                         500,000,000   500,000,000    
Common stock, par value (in Dollars per share)                         $ 0.0001   $ 0.0001    
Common stock, shares issued                         380,108,169   370,747,042    
Common stock, shares outstanding                         380,108,169   370,747,042    
Common stock value (in Dollars)                   $ 30,500,000              
Cover expenses (in Dollars)                   $ 15,000              
Common stock closing price, percentage                   15.00%              
Grant option exercisable                             20,000,000    
Number of vested shares                 2,500,000                
Stock option, description                             17,500,000 shares vest over the next 2 years, 2,500,000 shares per quarter.    
Stock option exercise price (in Dollars per share)                             $ 0.25    
Stock option expire term                             5 years    
Stock option outstanding intrinsic value (in Dollars)                         $ 0        
Stock options fair value the grant date (in Dollars per share)                         $ 2,127,565        
Stock price (in Dollars per share)                         $ 0.15   $ 0.11    
The total stock option expense (in Dollars)                         $ 262,157        
Total unamortized stock option expense (in Dollars)                         1,888,285        
Expenses paid on behalf of the Company and contributed to capital (in Dollars)                         90,956 $ 3,951      
Paid expenses (in Dollars)                         5,063 $ 21      
Total payments considered contributions (in Dollars)                         $ 8,126        
Series A Preferred Stock [Member]                                  
Shareholder Equity (Details) [Line Items]                                  
Preferred stock, shares issued                                 350,000
Series A preferred stock were issued                         700,000        
Shares of restricted common stock                         250,000,000        
Board of Directors [Member]                                  
Shareholder Equity (Details) [Line Items]                                  
Restricted common stock 125,000   125,000         125,000                  
Closing share price (in Dollars) $ 15,468   $ 15,000         $ 18,750                  
Jeffrey DeNunzio [Member]                                  
Shareholder Equity (Details) [Line Items]                                  
Paid expenses (in Dollars)                             $ 6,441 $ 1,185  
CRS Consulting, LLC [Member]                                  
Shareholder Equity (Details) [Line Items]                                  
Restricted common stock         250,000           50,000            
Closing share price (in Dollars)         $ 45,000           $ 7,000            
CRS Consulting, LLC [Member] | Series A Preferred Stock [Member]                                  
Shareholder Equity (Details) [Line Items]                                  
Series A preferred stock were issued                           700,000      
Sauer Energy, Inc. [Member]                                  
Shareholder Equity (Details) [Line Items]                                  
Common shares, outstanding                         359,996,332        
Green Ohio Ventures, LLC [Member]                                  
Shareholder Equity (Details) [Line Items]                                  
Restricted common stock           24,137,499         17,963,817 250,000,000          
SRAX, Inc [Member]                                  
Shareholder Equity (Details) [Line Items]                                  
Restricted common stock         2,602,740                        
Closing share price (in Dollars)         $ 468,493                        
Shareholders [Member]                                  
Shareholder Equity (Details) [Line Items]                                  
Restricted common stock   549,097                     325,000        
Proceeds total (in Dollars)   $ 68,000                     $ 40,248        
Mango Moi, LLC [Member]                                  
Shareholder Equity (Details) [Line Items]                                  
Restricted common stock             11,000,000                    
Closing share price (in Dollars)             $ 550,000                    
Williamsburg Venture Holdings LLC [Member]                                  
Shareholder Equity (Details) [Line Items]                                  
Common stock, shares issued       7,048,873                          
Purchase price of shares (in Dollars)       $ 250,000                          
Cancellation and return of common shares       7,048,873                          
Paul Moody [Member]                                  
Shareholder Equity (Details) [Line Items]                                  
Paid expenses (in Dollars)                             $ 500    
XML 35 R27.htm IDEA: XBRL DOCUMENT v3.22.2
Related-Party Transactions (Details) - USD ($)
3 Months Ended 12 Months Ended
May 31, 2022
Feb. 28, 2022
Related-Party Transactions (Details) [Line Items]    
Loans $ 271,738  
Ian James [Member]    
Related-Party Transactions (Details) [Line Items]    
Paid expenses   $ 65
Green Ohio Ventures, LLC [Member]    
Related-Party Transactions (Details) [Line Items]    
Paid expenses 165,444 $ 202,475
Payments 130,759  
Mango Moi, LLC [Member]    
Related-Party Transactions (Details) [Line Items]    
Paid expenses $ 35,000  
XML 36 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Impairment Expense (Details)
3 Months Ended
May 31, 2022
USD ($)
shares
Impairment Expense (Details) [Line Items]  
Fair market value $ 550,000
Impairment expense $ 577,473
Mango Moi, LLC [Member]  
Impairment Expense (Details) [Line Items]  
Common stock shares received (in Shares) | shares 11,000,000
Mango Moi’s assets and took [Member]  
Impairment Expense (Details) [Line Items]  
Company received amount $ 7,646
Mango Moi’s debts [Member]  
Impairment Expense (Details) [Line Items]  
Company received amount $ 35,119
XML 37 R29.htm IDEA: XBRL DOCUMENT v3.22.2
Subsequent Events (Details) - USD ($)
3 Months Ended
Jun. 07, 2022
May 31, 2022
Jul. 11, 2022
Apr. 12, 2022
Subsequent Events (Details) [Line Items]        
Purchase price   $ 254,250    
Original issue discount       $ 31,000
Maturity date   Jun. 07, 2023    
Commitment shares (in Shares)   4,960,000    
Purchase agreement description   In connection with the Purchase Agreements, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Mast Hill, pursuant to which the Company is obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the Commitment Shares and the shares of the Company’s common stock that may be issued to Mast Hill pursuant to the conversion of the Note.     
Agreement fees   $ 22,320    
Warrant coverage raised percentage   8.00%    
Exercise price percentage   120.00%    
Registration rights expires   5 years    
Purchase common shares (in Shares)   4,000,000    
Subsequent Event [Member]        
Subsequent Events (Details) [Line Items]        
Principal amount     $ 1  
Purchase price $ 279,000      
Original issue discount $ 31,000      
Interest rate 12.00%      
Conversion price per share (in Dollars per share) $ 0.037      
Common stock value (in Shares)     4,000,000  
Dr. Nicola Finley [Member]        
Subsequent Events (Details) [Line Items]        
Purchase common shares (in Shares)   4,000,000    
Securities Purchase Agreement [Member] | Subsequent Event [Member]        
Subsequent Events (Details) [Line Items]        
Principal amount $ 310,000      
XML 38 f10q0522_betterforyou_htm.xml IDEA: XBRL DOCUMENT 0001852707 2022-03-01 2022-05-31 0001852707 2022-08-04 0001852707 2022-05-31 0001852707 2022-02-28 0001852707 2021-03-01 2021-05-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0001852707 bfyw:SharesCancelableMember 2022-02-28 0001852707 us-gaap:NoncontrollingInterestMember 2022-02-28 0001852707 us-gaap:RetainedEarningsMember 2022-02-28 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-03-01 2022-05-31 0001852707 bfyw:SharesCancelableMember 2022-03-01 2022-05-31 0001852707 us-gaap:NoncontrollingInterestMember 2022-03-01 2022-05-31 0001852707 us-gaap:RetainedEarningsMember 2022-03-01 2022-05-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001852707 bfyw:SharesCancelableMember 2022-05-31 0001852707 us-gaap:NoncontrollingInterestMember 2022-05-31 0001852707 us-gaap:RetainedEarningsMember 2022-05-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-02-28 0001852707 us-gaap:NoncontrollingInterestMember 2021-02-28 0001852707 us-gaap:RetainedEarningsMember 2021-02-28 0001852707 2021-02-28 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-03-01 2021-05-31 0001852707 us-gaap:NoncontrollingInterestMember 2021-03-01 2021-05-31 0001852707 us-gaap:RetainedEarningsMember 2021-03-01 2021-05-31 0001852707 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001852707 us-gaap:NoncontrollingInterestMember 2021-05-31 0001852707 us-gaap:RetainedEarningsMember 2021-05-31 0001852707 2021-05-31 0001852707 bfyw:PredecessorsMember 2022-05-31 0001852707 bfyw:FastTrackSolutionsIncMember 2022-05-31 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-30 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:CommonStockMember 2021-07-01 2021-07-30 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember bfyw:CRSConsultingsLLCMember 2021-07-30 0001852707 bfyw:IanJamesMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:StephenLetourneauMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-07-30 0001852707 bfyw:PurchasePriceMember 2021-07-01 2021-07-30 0001852707 bfyw:PurchasePriceMember 2021-07-30 0001852707 bfyw:MRKTSGroupIncMember 2021-08-01 2021-08-24 0001852707 bfyw:PurchasePriceMember bfyw:MRKTSGroupIncMember 2021-08-24 0001852707 bfyw:BetterForYouWellnessIncMember 2021-08-01 2021-08-25 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-08-25 0001852707 2021-08-29 2021-09-01 0001852707 bfyw:MangoMoiLLCMember us-gaap:CommonStockMember 2022-04-29 0001852707 2022-04-29 0001852707 bfyw:AmandaCayemitteMember us-gaap:CommonStockMember 2022-04-29 0001852707 bfyw:YapoMbeMember us-gaap:CommonStockMember 2022-04-29 0001852707 bfyw:SRAXIncMember 2021-09-02 2021-09-17 0001852707 2022-04-18 0001852707 2022-04-01 2022-04-18 0001852707 bfyw:MastHillFundLPMember 2022-04-12 2022-04-12 0001852707 bfyw:MastHillFundLPMember 2022-04-12 0001852707 2022-04-12 0001852707 2022-04-12 2022-04-12 0001852707 bfyw:CRSConsultingLLCMember us-gaap:SeriesAPreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember 2021-11-30 0001852707 bfyw:SauerEnergyIncMember 2022-05-31 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-07-01 2021-07-19 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-23 2021-08-25 0001852707 bfyw:CRSConsultingLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:SRAXIncMember 2021-10-01 2021-10-11 0001852707 bfyw:CRSConsultingLLCMember 2021-10-01 2021-10-11 0001852707 pf0:BoardOfDirectorsChairmanMember 2021-11-01 2021-11-17 0001852707 pf0:BoardOfDirectorsChairmanMember 2021-12-25 2022-01-03 0001852707 us-gaap:MajorityShareholderMember 2022-01-01 2022-01-13 0001852707 pf0:BoardOfDirectorsChairmanMember 2022-04-01 2022-04-12 0001852707 bfyw:MangoMoiLLCMember 2022-05-01 2022-05-26 0001852707 us-gaap:MajorityShareholderMember 2022-03-01 2022-05-31 0001852707 2021-09-02 2021-09-17 0001852707 2021-09-17 0001852707 bfyw:WilliamsburgVentureHoldingsLLCMember 2021-12-02 0001852707 bfyw:WilliamsburgVentureHoldingsLLCMember 2021-12-01 2021-12-02 0001852707 2021-09-02 2021-09-30 0001852707 2021-03-01 2022-02-28 0001852707 bfyw:JeffreyDeNunzioMember 2021-03-01 2022-02-28 0001852707 bfyw:PaulMoodyMember 2021-03-01 2022-02-28 0001852707 bfyw:JeffreyDeNunzioMember 2020-03-01 2021-02-28 0001852707 bfyw:IanJamesMember 2021-03-01 2022-02-28 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-03-01 2022-02-28 0001852707 bfyw:GreenOhioVenturesLLCMember 2022-03-01 2022-05-31 0001852707 bfyw:MangoMoiLLCMember 2022-03-01 2022-05-31 0001852707 bfyw:MangoMoiLLCMember 2022-05-31 0001852707 bfyw:MangoMoisAssetsAndTookMember 2022-03-01 2022-05-31 0001852707 bfyw:MangoMoisDebtsMember 2022-03-01 2022-05-31 0001852707 bfyw:SecuritiesPurchaseAgreementMember us-gaap:SubsequentEventMember 2022-06-07 0001852707 us-gaap:SubsequentEventMember 2022-06-02 2022-06-07 0001852707 us-gaap:SubsequentEventMember 2022-06-07 0001852707 us-gaap:SubsequentEventMember 2022-07-11 0001852707 bfyw:DrNicolaFinleyMember 2022-05-31 shares iso4217:USD iso4217:USD shares pure iso4217:USD compsci:item 10-Q true 2022-05-31 2022 false 000-56262 better for you wellness, Inc. NV 87-2903933 1349 East Broad Street Columbus OH 43205 (614) 368-9898 Yes Yes Non-accelerated Filer true true false false 385198451 2695 9719 7037 13106 9732 22825 607 731 10338 23555 306738 305666 315063 5385 36366 119 11150 16217 172933 674503 495133 0.0001 0.0001 200000000 200000000 700000 700000 700000 700000 70 70 0.0001 0.0001 500000000 500000000 380108169 380108169 38011 37075 -250000 2419264 1485364 4358 -3121510 -1748445 -664165 -471578 10338 23555 13087 19455 10268 7230 2819 12226 240576 23692 577473 516407 70000 1334455 93692 10 36366 5063 21 -41429 -11 -1373066 -81477 0 0 363657794 195652174 370747042 37075 700000 70 1485364 -250000 4358 -1748445 -471578 -7048873 -705 -249295 250000 325000 33 -33 5085000 509 253742 254250 11000000 1100 576373 577473 262157 262157 90956 90956 -4358 -1373066 -1373066 380108169 38011 700000 70 2419264 -3121510 -664165 1185 -57150 -55965 359996332 36000 -36000 700000 700 69930 70000 3951 3951 20768 20768 -81477 -81477 359996332 36000 700000 700 39066 20768 -138627 -42723 -1373066 -81477 254250 70000 577473 36366 262157 5063 156716 2630 5385 15039 89286 -10893 32 -404695 -30358 310000 -4358 20768 90956 3951 1072 397671 24719 -7024 -5640 9719 8348 2695 2708 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Note 1 - Organization and Description of Business</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Better For You Wellness, Inc. </span>(“we,” “us,” “our”, the “Company” or the “Registrant”) <span>was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Our former director, Jeffrey DeNunzio, was the sole director/officer of each constituent corporation in the Reorganization.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021, at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until the new ticker symbol “FTRK” for the Company was released into the OTC MarketPlace on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company believes that the Reorganization, deemed effective on May 5, 2021, was not a transaction of the type described in subparagraph (a) of Rule 145 under the Securities Act of 1933 and the consummation of the Reorganization will not be deemed to involve an “offer”, “offer to sell”, “offer for sale” or “sale” within the meaning of Section 2(3) of the Securities Act of 1933. The Reorganization was consummated without the vote or consent of the Company’s stockholders. In addition, the provisions of NRS 92A.180 did not provide a stockholder of the Company with appraisal rights in connection with the Reorganization. The Company believes that in the absence of any right of any of the Company’s stockholders to vote with respect to the Reorganization or to insist that their shares be purchased for fair value, the Reorganization could not be deemed to involve an “offer” “offer to sell”; or “sale” within the meaning of Section 2(3) of the Securities Act of 1933.”</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On May 5, 2021, after the completion of the Holding Company Reorganization, we canceled all of the stock we held in Sauer Energy, Inc., resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Given that the former business plan and objectives of Sauer Energy, Inc. and the business plan and objectives of Fast Track Solutions, Inc. substantially differed from one another, we conducted the corporate separation with Sauer Energy, Inc. immediately after the effective time of the Reorganization in order to avoid any shareholder confusion. The former business plan of Sauer Energy, Inc. (the development and marketing of wind powered electric generators) under the leadership of its former directors, did not, in any way, represent the blank check business plan of Fast Track Solutions, Inc. at that time, and thus it is the belief of the Company that the corporate separation ameliorated shareholder confusion about our identity and/or corporate objectives. It is our belief that Sauer Energy was a shell company at the time of the Reorganization.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The corporate actions taken by the Company, including, but not limited to, the corporate structuring of the transactions, was deemed, in the discretion of our sole director, to be for the benefit of the corporation and its shareholders. Former shareholders of Sauer Energy, Inc. were then the shareholders of Fast Track Solutions, Inc. and had the opportunity to benefit from a business combination with another company. The Company intended to serve as a vehicle to affect an asset acquisition, merger, exchange of capital stock or other business combination with a domestic or foreign business at that time</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span> </span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>After the reorganization and through July 18, 2021, CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody, was our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On July 19, 2021, Better For You Wellness, Inc., FKA “Fast Track Solutions, Inc.”, a Nevada Corporation (the “Company”), entered into a Share Purchase Agreement (the “Agreement”) by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021 (“Closing Date”), CRS sold 700,000 shares of the Company’s Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of the Company; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000) (the “Purchase Price”). The consummation of the transactions contemplated by the Agreement resulted in a change in control of the Company, with GOHV, Ian James, and Stephen Letourneau, becoming the Company’s largest controlling stockholders having approximately 89.62% combined voting control over the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Pursuant to the Agreement, on July 30, 2021, Mr. Jeffrey DeNunzio resigned as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Director.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On July 30, 2021, Mr. Ian James was appointed as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors and Mr. Stephen Letourneau was appointed as a Director.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On August 19, 2021, the Company filed an 8-K with the SEC to disclose an amendment to the Company’s Articles of Incorporation that the Company filed on August 18, 2021, with the Nevada Secretary of State to change its name to Better For You Wellness, Inc. Within the aforementioned 8-K, the Company disclosed that, at the time, it was pending a FINRA corporate action to affect the name change on the OTC to Better For You Wellness, Inc., and also a ticker symbol change. FINRA announced, on their September 29, 2021 daily list, that the market effective date of our name change, and ticker symbol change, will be September 30, 2021. On September 30, 2021, we will begin trading under the symbol BFYW. The new CUSIP number associated with our common stock, as of the market effective date of September 30, 2021, is 08771B105.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided. This transaction did not result in MRKTS Group Inc. owning 5% or more of any class of securities of the issuer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau. The aforementioned transaction(s) did not result in any individual shareholder owning 5% or more of any class of securities of the issuer. The aforementioned transaction was carried out as it was deemed by GOHV to be in the best interests of its members.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On August 27, 2021, Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On September 1, 2021, we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per annum, paid in equal $250 distributions quarterly, and 200,000 shares of common stock, issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share. The Directors were officially seated September 12, 2021, after notification to shareholders. On December 14, 2021, the Company’s Board of Directors unanimously approved the appointment of Christina Jefferson to the Board as an Independent Director, effective January 1, 2022. Christina Jefferson replaced Leslie Bumgarner whose resignation, as previously announced, became effective December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span>On February 3. 2022, the Company was approved by OTC Markets to up-list its common stock from the OTC Pink Sheets to the OTCQB® Venture Market (the “OTCQB”). The Company began trading of its common shares on the OTCQB as of the market open on February 3, 2022, under its same symbol, “BFYW.”</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On February 5, 2022, the Company’s Board of Directors unanimously approved the establishment of a Strategic Advisory Committee. The Board appointed six initial members by unanimous consent including David King, Laurie Racine, Zhiping Zhang, Melisse Gelula, Christopher Brown, and Kate Hendrickson.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Also on February 5, 2022, by unanimous vote of the Company’s Board of Directors’ five non-executive Independent Directors, David Deming was appointed Chairperson of the Company’s Audit Committee, which follows the Board’s October 1, 2021, unanimous consent to establish the Audit Committee. The Audit Committee currently consists of three non-executive Independent Directors, including Montel Williams, Joseph Watson, and David Deming. Also, by unanimous vote of the Board’s five non-executive Independent Directors, Christina Jefferson was appointed to the Company’s Compensation Committee, filling the vacancy left by former Director Leslie Bumgarner. This action follows the Board’s October 1, 2021, unanimous consent to establish the Compensation Committee. The Compensation Committee currently consists of Independent Directors, Christina Jefferson, Montel Williams, and Joseph Watson. Additionally, the Board’s five non-executive Independent Directors unanimously appointed Joseph Watson as Chairperson of the Compensation Committee.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company’s current business plan is to explore and evaluate various opportunities in the plant-based food and beverage and consumer packaged goods sectors, including but not limited to, mergers, acquisitions, or business combination transactions, after which the Company would cease to be a “shell” or “blank check” company. The Company’s principal business objective for the next 12 months and beyond will be to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On November 15, 2021, the Company’s wholly owned subsidiary, Glow Market, LLC was formed in the State of Ohio. Subsequently, Glow Market, LLC launched its first brand, Better Suds, an online retailer of specialty all-natural, cruelty-free, gluten-free and chemical-free soaps. Better Suds commenced operations in December 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On April 29, 2022 the Company entered into a Membership Interest Purchase Agreement (the “MIPA”) with Amanda Cayemitte and Yapo M’be (referred to together as the “Sellers”) to acquire the right, title and interest in, including all of the outstanding membership interests (referred to together as the “MM Interests”) of Mango Moi, LLC (“Mango Moi”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Mango Moi is a hair and skincare business located in Chicago, Illinois. Pursuant to the MIPA, in exchange for the MM Interests, the Company agreed to pay the Sellers a purchase price consisting of shares of the Company’s common stock, par value $0.0001 per share which consists of 11,000,000 shares of common stock (the “Company Common Stock”), with a fair market value of approximately $550,000, with 5,720,000 shares of Company Common Stock issued to Amanda Cayemitte and 5,280,000 shares of Company Common Stock issued to Yapo M’be (referred to together herein as the “Purchase Price”). Additionally, pursuant to the terms of the MIPA, the Company agreed to enter into an Employment Agreement with Mango Moi founder Amanda Cayemitte (the “Employment Agreement”), and a Consulting Agreement with Yapo M’be  (the “Consulting Agreement”), respectively, as disclosed by the Company on its Current Report on Form 8-K filed with the SEC on May 2, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The MIPA closed (the “Closing”) on May 26, 2022, on which date the Company paid the Sellers the Purchase Price by issuing the Company Common Stock to the Sellers and the Sellers transferred the MM Interests to the Company, and on which date Mango Moi became a wholly owned subsidiary of the Company. At the Closing the Company entered into the Employment Agreement with Amanda Cayemitte and the Consulting Agreement with Yapo M’be.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company intends to optimize Mango Moi’s product formulae and packaging, as well as secure new manufacturing relationships to scale production capacity. Additionally, the Company plans to expand Mango Moi’s product offerings to include additional products and product bundles. Furthermore, the Company intends to grow sales through direct-to-consumer marketing efforts, subscription box sales, and pursuing wholesale sales relationships. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company’s main office is located at 1349 East Broad Street, Columbus OH 43205.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company has elected February 28th as its year end.</span></p> 1000 1000 700000 250000000 700000 250000000 0.8962 350000 350000 250000000 335000 0.8962 17963817 0.05 24137499 0.05 we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per annum, paid in equal $250 distributions quarterly, and 200,000 shares of common stock, issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share. 0.0001 11000000 550000 5720000 5280000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Note 2 - Summary of Significant Accounting Policies</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Principles of Consolidation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Glow Markets, LLC and Mango Moi, LLC. All significant intercompany accounts and transactions have been eliminated.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Basis of Presentation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Cash and Cash Equivalents</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at May 31, 2022 and February 28, 2022 were $2,695 and $9,719 respectively.<b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span><b>Revenue recognition</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Revenue for products is recognized when the products are delivered to the customer and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of May 31, 2022, the Company had no deferred revenues. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Income Taxes</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company accounts for income taxes under ASC 740, “<i>Income Taxes</i>.”  Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs.  A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at May 31, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Basic Earnings (Loss) Per Share</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, <i>Earnings per Share</i>. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company does not have any potentially dilutive instruments as of May 31, 2022 and, thus, anti-dilution issues are not applicable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Fair Value of Financial Instruments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>ASC 820, <i>Fair Value Measurements and Disclosures</i>, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-variant: small-caps"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span><b>Related Parties</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company follows ASC 850, <i>Related Party Disclosures,</i> for the identification of related parties and disclosure of related party transactions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Share-Based Compensation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>ASC 718, “<i>Compensation – Stock Compensation</i>”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “<i>Equity – Based Payments to Non-Employees.”</i>  Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable:  (a) the goods or services received; or (b) the equity instruments issued.  The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company had no stock-based compensation plans as of May 31, 2022 and February 28, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s stock-based compensation for the period ended May 31, 2022 and May 31, 2021 was $516,407<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span> <span>and $70,000, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Recently Issued Accounting Pronouncements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In February 2016, the FASB issued ASU 2016-02, <i>Leases (Topic 842). ASU 2016-02</i> is amended by ASU 2018-01, ASU2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01, which FASB issued in January 2018, July 2018, July 2018, December 2018 and March 2019, respectively (collectively, the amended ASU 2016-02). The amended ASU 2016-02 requires lessees to recognize on the balance sheet a right-of-use asset, representing its right to use the underlying asset for the lease term, and a lease liability for all leases with terms greater than 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from current GAAP. The amended ASU 2016-02 retains a distinction between finance leases (i.e. capital leases under current GAAP) and operating leases. The classification criteria for distinguishing between finance leases and operating leases will be substantially similar to the classification criteria for distinguishing between capital leases and operating leases under current GAAP. The amended ASU 2016-02 also requires qualitative and quantitative disclosures designed to assess the amount, timing, and uncertainty of cash flows arising from leases. A modified retrospective transition approach is permitted to be used when an entity adopts the amended ASU 2016-02, which includes a number of optional practical expedients that entities may elect to apply.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>We have no assets and or leases and do not believe we will be impacted in the foreseeable future by the newly adopted accounting standard(s) mentioned above.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Principles of Consolidation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Glow Markets, LLC and Mango Moi, LLC. All significant intercompany accounts and transactions have been eliminated.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Basis of Presentation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Cash and Cash Equivalents</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at May 31, 2022 and February 28, 2022 were $2,695 and $9,719 respectively.<b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p> 2695 9719 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span><b>Revenue recognition</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Revenue for products is recognized when the products are delivered to the customer and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of May 31, 2022, the Company had no deferred revenues. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Income Taxes</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company accounts for income taxes under ASC 740, “<i>Income Taxes</i>.”  Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs.  A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at May 31, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Basic Earnings (Loss) Per Share</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, <i>Earnings per Share</i>. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company does not have any potentially dilutive instruments as of May 31, 2022 and, thus, anti-dilution issues are not applicable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Fair Value of Financial Instruments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>ASC 820, <i>Fair Value Measurements and Disclosures</i>, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-variant: small-caps"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span><b>Related Parties</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company follows ASC 850, <i>Related Party Disclosures,</i> for the identification of related parties and disclosure of related party transactions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Share-Based Compensation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>ASC 718, “<i>Compensation – Stock Compensation</i>”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “<i>Equity – Based Payments to Non-Employees.”</i>  Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable:  (a) the goods or services received; or (b) the equity instruments issued.  The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company had no stock-based compensation plans as of May 31, 2022 and February 28, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s stock-based compensation for the period ended May 31, 2022 and May 31, 2021 was $516,407<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span> <span>and $70,000, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p> 516407 70000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Recently Issued Accounting Pronouncements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In February 2016, the FASB issued ASU 2016-02, <i>Leases (Topic 842). ASU 2016-02</i> is amended by ASU 2018-01, ASU2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01, which FASB issued in January 2018, July 2018, July 2018, December 2018 and March 2019, respectively (collectively, the amended ASU 2016-02). The amended ASU 2016-02 requires lessees to recognize on the balance sheet a right-of-use asset, representing its right to use the underlying asset for the lease term, and a lease liability for all leases with terms greater than 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from current GAAP. The amended ASU 2016-02 retains a distinction between finance leases (i.e. capital leases under current GAAP) and operating leases. The classification criteria for distinguishing between finance leases and operating leases will be substantially similar to the classification criteria for distinguishing between capital leases and operating leases under current GAAP. The amended ASU 2016-02 also requires qualitative and quantitative disclosures designed to assess the amount, timing, and uncertainty of cash flows arising from leases. A modified retrospective transition approach is permitted to be used when an entity adopts the amended ASU 2016-02, which includes a number of optional practical expedients that entities may elect to apply.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>We have no assets and or leases and do not believe we will be impacted in the foreseeable future by the newly adopted accounting standard(s) mentioned above.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Note 3 - Going Concern</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company has not established enough sources of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to capital. There is no assurance that management’s plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Note 4 - Income Taxes</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the period presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not. As of May31, 2022, the Company has incurred a net loss of approximately $3,121,510 which resulted in a net operating loss for income tax purposes.  The loss results in a deferred tax asset of approximately $655,517 at the effective statutory rate of 21%. The deferred tax asset has been offset by an equal valuation allowance. Given our inception on December 1, 2020, and our fiscal year end of February 28, 2022, we have completed only two taxable fiscal years.</span></p> 3121510 655517 0.21 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span><b>Note 5 - Commitments and Contingencies</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company follows ASC 450-20, <i>Los</i>s<i> Contingencies, </i>to report accounting for contingencies.  Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of May 31, 2022 other than the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Also on September 17, 2021, our Board of Directors unanimously agreed to approve to enter into and consummate another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On April 18, 2022, Better For You Wellness, Inc., a Nevada corporation (the “Company”), entered into a Standby Equity Commitment Agreement, dated April 11, 2022 (the “SECA”) with MacRab LLC, a Florida limited liability company (the “Investor”). The SECA provides the Company with an option to sell up to $5,000,000 worth of the Company’s common stock, par value $0.0001 (the “Common Stock”), to the Investor, in increments, over the period ending twenty-four (24) months after the date the Registration Statement (as defined below) is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. The purchase price per share, for each respective put under the SECA, is equal to 90% of the average of the two (2) lowest volume weighted average prices of the Common Stock during the six (6) trading days following the clearing date associated with the respective put under the SECA. Additionally, we issued a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock (the “Warrant”) to Investor as a commitment fee in connection with the execution of the SECA.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On May 26, 2022 the Company acquired Mango Moi, LLC as a wholly-owned subsidiary (See Note 1). As part of the purchase agreement, the Company entered into an employment agreement and a consulting agreement as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Employment Agreement</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Pursuant to the Employment Agreement, which is to be effective as of 45 days from the signing of the MIPA, the Company agreed to employ Amanda Cayemitte as the Chief Visionary Officer of Mango Moi to provide duties including normalizing the Company’s strategic-planning processes, forging new working relationships and synergies across the organization, and establishing greater transparency and accountability for those people carrying out the Company’s strategy. As compensation under the Employment Agreement, the Company agreed to pay Amanda Cayemitte  an annual salary of $65,000 payable semi-monthly on the first day and the fifteenth day of the month and subject to applicable federal, state, and local withholding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Employment Agreement can be terminated any time by either party by giving 30 days written notice to the other party.  If the Employment Agreement is terminated, Amanda Cayemitte will be entitled to receive compensation for:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify; "> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">one month upon completion of one full calendar year of employment with the Company;</td> </tr></table><p style="margin-top: 0; margin-bottom: 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">two months upon completion of two full calendar years of employment with the Company, and</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify; "> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">three months upon competition of two full calendar years of employment with the Company.</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">However, if Amanda Cayemitte breaches any terms of the Employment Agreement, the Company may terminate the Employment Agreement without any notice and with compensation being paid to Amanda Cayemitte only through the date of such termination. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Consulting Agreement</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Pursuant to the Consulting Agreement, the Company engaged Yapo M’be as a consultant to provide manufacturing services for Mango Moi, to begin on May 2, 2022.  As compensation under the Consulting Agreement, the Company agreed to pay Yapo M’be at the rate of $30.00 per hour, not to exceed $1,500 per month.  The Consulting Agreement can be terminated by either party upon the failure of the other to perform under the Consulting Agreement by giving ten days written notice to the non-performing party. The Consulting Agreement can also be terminated by the Company by giving ten days written notice to Yapo M’be in the event that there is a reduction of the program budget. </p> 20000 5000000 0.0001 0.90 1785714 65000 Pursuant to the Consulting Agreement, the Company engaged Yapo M’be as a consultant to provide manufacturing services for Mango Moi, to begin on May 2, 2022.  As compensation under the Consulting Agreement, the Company agreed to pay Yapo M’be at the rate of $30.00 per hour, not to exceed $1,500 per month. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Note 6 – Convertible Note Payable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On April 12, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreements”) with Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”), respectively, pursuant to which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on April 12, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.</span></p> 310000 279000 31000 0.12 2023-04-12 0.037 4960000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Note 7 – Stock Purchase Warrant Liability</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On April 18, 2022, Better For You Wellness, Inc., a Nevada corporation (the “Company”), entered into a Standby Equity Commitment Agreement, dated April 11, 2022 (the “SECA”) with MacRab LLC, a Florida limited liability company (the “Investor”). The SECA provides the Company with an option to sell up to $5,000,000 worth of the Company’s common stock, par value $0.0001 (the “Common Stock”), to the Investor, in increments, over the period ending twenty-four (24) months after the date the Registration Statement (as defined below) is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. The purchase price per share, for each respective put under the SECA, is equal to 90% of the average of the two (2) lowest volume weighted average prices of the Common Stock during the six (6) trading days following the clearing date associated with the respective put under the SECA. Additionally, we issued a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock (the “Warrant”) to Investor as a commitment fee in connection with the execution of the SECA.The Company fair valued the shares purchase warrant on the closing date at $36,366 using a Black-Scholes put option pricing model.</span></p> Better For You Wellness, Inc., a Nevada corporation (the “Company”), entered into a Standby Equity Commitment Agreement, dated April 11, 2022 (the “SECA”) with MacRab LLC, a Florida limited liability company (the “Investor”). The SECA provides the Company with an option to sell up to $5,000,000 worth of the Company’s common stock, par value $0.0001 (the “Common Stock”), to the Investor, in increments, over the period ending twenty-four (24) months after the date the Registration Statement (as defined below) is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. The purchase price per share, for each respective put under the SECA, is equal to 90% of the average of the two (2) lowest volume weighted average prices of the Common Stock during the six (6) trading days following the clearing date associated with the respective put under the SECA. Additionally, we issued a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock (the “Warrant”) to Investor as a commitment fee in connection with the execution of the SECA.The Company fair valued the shares purchase warrant on the closing date at $36,366 using a Black-Scholes put option pricing model. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span><b>Note 8 - Shareholder Equity </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Preferred Stock</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The authorized preferred stock of the Company consists of 200,000,000 shares with a par value of $0.0001. There were 700,000 shares issued and outstanding as of May31, 2022 and February 28, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>During the three months ended May 31, 2021, 700,000 shares of Series A Preferred Stock were issued to CRS Consulting, LLC (“CRS”), a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody. CRS is our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock. Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock. On July 19, 2021, these shares were purchased. As of November 30, 2021, our CEO, Ian James, and Director, Stephen Letourneau, each hold 350,000 shares of Series A Preferred Stock (See Note 1).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Common Stock</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The authorized common stock of the Company consists of 500,000,000 shares with a par value of $0.0001. There were 380,108,169 and 370,747,042 shares of common stock issued and outstanding as of May31, 2022 and February 28, 2022, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>At the time of reorganization, former shareholders of Sauer Energy, Inc. became shareholders of Fast Track Solutions, Inc., representing 359,996,332 of the common shares outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On July 19, 2021, 250,000,000 shares of restricted Common Stock were purchased by Ohio Green Ventures, LLC from CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody (See Note 1).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau (See Note 1).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On August 24, 2021, 50,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $7,000.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On October 11, 2021, 2,602,740 shares of Restricted Common Stock were issued to SRAX, Inc as compensation for marketing services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $468,493.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On October 11, 2021, 250,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $45,000.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On November 17, 2021, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $18,750.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On January 3, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $15,000.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On January 13, 2022, 549,097 shares of Restricted Common Stock were sold to five shareholders for proceeds totaling $68,000.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On April12, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled approximately $15,468.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On May 26, 2022, 11,000,000 share of Restricted Common Stock were issued to the two Sellers of Mango Moi, LLC (See Note 1). The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled approximately $550,000.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>During the period ended May 31, 2022, a total of 325,000 shares of Restricted Common Stock were sold to two shareholders for proceeds totaling approximately $40,248.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Shares Cancelable</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate a “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet was a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet was for 36 months. Following the execution of the term sheet, the Company was to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH was to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On December 2, 2021 7,048,873 shares of common stock were issued to WVH in order to honor the above agreement. However, WVH did not transfer the $250,000 purchase price of the shares to the Company and on April 12, 2022 an agreement to terminate the previous agreement was signed. On April 13, 2022 the Company forwarded a cancellation order to its transfer agent, which authorized the cancellation and return of 7,048,873 common shares previously issued to WVH. As of the date of filing, these shares have been canceled and returned to the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Stock Options</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>During the fiscal year ended February 28, 2022, the Company granted options exercisable for up to 20,000,000 shares of Common Stock of which 2,500,000 fully vested on September 30, 2021. 17,500,000 shares vest over the next 2 years, 2,500,000 shares per quarter. The options have the exercise price of $.25 per share. These options expire 5 years after issue. The aggregate intrinsic value of these outstanding options as of May 31, 2022, was $0.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company fair valued the options on the grant dates at $2,127,565 using a Black-Scholes option pricing model with the following assumptions: stock price of $.15 and $.11 per share (based on the quoted trading price on the dates of the grants). The Company is amortizing the expense over the vesting terms of each. The total stock option expense for the period ended May 31, 2022 was approximately $262,157. The total unamortized stock option expense at May 31, 2022 was approximately $1,888,285.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Additional Paid-In Capital</i></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the quarterly period ended May 31, 2022, the Sellers of Mango Moi, LLC, paid prior expenses on behalf of the wholly-owned subsidiary totaling approximately $90,956. These payments are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totaling $6,441 during the year ended February28, 2022. During the year ended February 28, 2022, former related party Paul Moody paid expenses on behalf of the Company totaling $500.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totaling $1,185 during the year ended February 28, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The $8,126 in total payments made by the former dir<span>ectors are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.</span></p> 200000000 0.0001 700000 700000 700000 700000 700000 700000 250000000 Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock. 350000 500000000 0.0001 380108169 380108169 370747042 370747042 359996332 250000000 17963817 24137499 50000 7000 2602740 468493 250000 45000 125000 18750 125000 15000 549097 68000 125000 15468 11000000 550000 325000 40248 30500000 15000 0.15 7048873 250000 7048873 20000000 2500000 17,500,000 shares vest over the next 2 years, 2,500,000 shares per quarter. 0.25 P5Y 0 2127565 0.15 0.11 262157 1888285 90956 6441 500 1185 8126 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Note 8 - Related-Party Transactions</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Loan to Company</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>During the period ended February 28, 2022, our CEO, Ian James, paid expenses on behalf of the Company totaling $65 and shareholder, Green Ohio Ventures, LLC, paid expenses on behalf of the Company totaling $202,475. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>During the period ended May 31, 2022, Green Ohio Ventures, LLC, paid expenses on behalf of the Company totaling approximately $165,444 and the Company made payments to Green Ohio Ventures, LLC, totaling approximately $130,759, which resulted in a net increase of the loan amount to a total of approximately $271,738. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>These payments are considered as loans to the Company, which are noninterest-bearing, unsecured and payable on demand.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In addition, the Company acquired $35,000 of a loan to Mango Moi, LLC when it became a wholly-owned subsidiary of the Company. This loan was made to Mango Moi, LLC by a relative of </span>Amanda Cayemitte, one of the sellers of the subsidiary.</p> 65 202475 165444 130759 271738 35000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Note 9 - Impairment Expense</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>During the period ended May 31, 2022, the Company purchased Mango Moi, LLC (“Mango Moi”) as a wholly-owned subsidiary. The sellers of Mango Moi received 11,000,000 shares of common stock with a fair market value of approximately $550,000. The Company received approximately $7,646 of Mango Moi’s assets and took on approximately $35,119 of Mango Moi’s debts. The Company posted the net value of Mango Moi’s liabilities and the fair market value of the shares issued to the sellers as an impairment expense of $577,473.</span></p> 11000000 550000 7646 35119 577473 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Note 10 - Subsequent Events</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On June 7, 2022, Better For You Wellness, Inc. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreements”) with Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”), respectively, pursuant to which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on June 7, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on June 7, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">In connection with the Purchase Agreements, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Mast Hill, pursuant to which the Company is obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the Commitment Shares and the shares of the Company’s common stock that may be issued to Mast Hill pursuant to the conversion of the Note.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">JH Darbie &amp; Co., Inc. (“JH Darbie”) and the Company are parties to a Finder’s Fee Agreement, signed March 15, 2020 (“Finder’s Agreement”) pursuant to which JH Darbie would introduce the Issuer to third-party investors. Pursuant to the Finder’s Agreement,  fees of approximately $22,320.00 were paid to JH Darbie. In addition, JH Darbie is to receive non-callable warrants of equal to 8% warrant coverage of the amount raised. The warrants shall entitle JH Darbie thereof to purchase common stock of the Company at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of the Issuer’s common stock on the date of the Transaction, whichever is lower (such price, the “Warrant Price”). The warrants shall be exercisable immediately after the date of issuance, shall have anti-dilutive price protection, participating registration rights, and shall expire 5 years after the date of issuance, in accordance with the Finder’s Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On June 18, 2022, Dr. Nicola Finley advised the Company’s board of directors that she will resign as a board member of the Company and that her resignation is effective immediately. Dr Finley also notified the board of directors of her willingness to voluntarily relinquish the compensatory options referenced in her Director Agreement dated August 29, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The resignation of Dr. Finley was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On June 20, 2022, the Company’s board of directors unanimously approved the appointment of Melisse Gelula as a non-executive independent director of the Company, effective immediately.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On July 11, 2022, the Company entered into a Common Share Option Cancellation and Forfeiture Agreement with former Director Dr. Nicola Finley (the “Option Cancellation and Forfeiture Agreement”). Under the Option Cancellation and Forfeiture Agreement, Dr. Nicola Finley forfeited, and the Company canceled Dr. Nicola Finley’s option to purchase 4,000,000 common shares of the Company that was granted to the optionee pursuant to the Director Agreement dated as of August 29, 2021. Upon such forfeiture and cancellation, Dr. Nicola Finley has no further rights to exercise the option to purchase 4,000,000 common shares of the Company. The cancellation and forfeiture set forth in the Option Cancellation and Forfeiture Agreement shall not affect the restricted common shares granted by the Company to Dr. Nicola Finley pursuant to the Director Agreement dated as of August 29, 2021. As a payment in lieu of whatever benefits, if any, to which Dr. Nicola Finley may have been entitled to under the option to purchase 4,000,000 common shares of the Company, the Company shall pay Dr. Nicola Finley $1.00.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On July 19, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Ian James, the Company’s Chief Executive Officer and the Company entered into the Agreement with Mr. James as of July 21, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Stephen Letourneau, the Company’s Chief Branding Officer and the Company entered into the Agreement with Mr. Letourneau as of July 21, 2022.</p> 310000 279000 31000 0.12 2023-06-07 0.037 4960000 In connection with the Purchase Agreements, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Mast Hill, pursuant to which the Company is obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the Commitment Shares and the shares of the Company’s common stock that may be issued to Mast Hill pursuant to the conversion of the Note.  22320 0.08 1.20 P5Y 4000000 4000000 4000000 1 370747042 370747042 0.00 0.00 195652174 363657794 false --02-28 Q1 0001852707 EXCEL 39 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 40 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 41 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 42 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 105 204 1 false 35 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.betterforyouwellness.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheet Sheet http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheet Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheet (Parentheticals) Sheet http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals Consolidated Balance Sheet (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statement of Operations Sheet http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement Consolidated Statement of Operations Statements 4 false false R5.htm 004 - Statement - Consolidated Statement of Operations (Parentheticals) Sheet http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement_Parentheticals Consolidated Statement of Operations (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Consolidated Statement of Changes in Stockholders??? Equity (Deficit) Sheet http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3 Consolidated Statement of Changes in Stockholders??? Equity (Deficit) Statements 6 false false R7.htm 006 - Statement - Consolidated Statement of Cash Flows Sheet http://www.betterforyouwellness.com/role/ConsolidatedCashFlow Consolidated Statement of Cash Flows Statements 7 false false R8.htm 007 - Disclosure - Organization and Description of Business Sheet http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 8 false false R9.htm 008 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Going Concern Sheet http://www.betterforyouwellness.com/role/GoingConcern Going Concern Notes 10 false false R11.htm 010 - Disclosure - Income Taxes Sheet http://www.betterforyouwellness.com/role/IncomeTaxes Income Taxes Notes 11 false false R12.htm 011 - Disclosure - Commitments and Contingencies Sheet http://www.betterforyouwellness.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 12 false false R13.htm 012 - Disclosure - Convertible Note Payable Sheet http://www.betterforyouwellness.com/role/ConvertibleNotePayable Convertible Note Payable Notes 13 false false R14.htm 013 - Disclosure - Stock Purchase Warrant Liability Sheet http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiability Stock Purchase Warrant Liability Notes 14 false false R15.htm 014 - Disclosure - Shareholder Equity Sheet http://www.betterforyouwellness.com/role/ShareholderEquity Shareholder Equity Notes 15 false false R16.htm 015 - Disclosure - Related-Party Transactions Sheet http://www.betterforyouwellness.com/role/RelatedPartyTransactions Related-Party Transactions Notes 16 false false R17.htm 016 - Disclosure - Impairment Expense Sheet http://www.betterforyouwellness.com/role/ImpairmentExpense Impairment Expense Notes 17 false false R18.htm 017 - Disclosure - Subsequent Events Sheet http://www.betterforyouwellness.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 018 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies 19 false false R20.htm 019 - Disclosure - Organization and Description of Business (Details) Sheet http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails Organization and Description of Business (Details) Details http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness 20 false false R21.htm 020 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details 21 false false R22.htm 021 - Disclosure - Income Taxes (Details) Sheet http://www.betterforyouwellness.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.betterforyouwellness.com/role/IncomeTaxes 22 false false R23.htm 022 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.betterforyouwellness.com/role/CommitmentsandContingencies 23 false false R24.htm 023 - Disclosure - Convertible Note Payable (Details) Sheet http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails Convertible Note Payable (Details) Details http://www.betterforyouwellness.com/role/ConvertibleNotePayable 24 false false R25.htm 024 - Disclosure - Stock Purchase Warrant Liability (Details) Sheet http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiabilityDetails Stock Purchase Warrant Liability (Details) Details http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiability 25 false false R26.htm 025 - Disclosure - Shareholder Equity (Details) Sheet http://www.betterforyouwellness.com/role/ShareholderEquityDetails Shareholder Equity (Details) Details http://www.betterforyouwellness.com/role/ShareholderEquity 26 false false R27.htm 026 - Disclosure - Related-Party Transactions (Details) Sheet http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails Related-Party Transactions (Details) Details http://www.betterforyouwellness.com/role/RelatedPartyTransactions 27 false false R28.htm 027 - Disclosure - Impairment Expense (Details) Sheet http://www.betterforyouwellness.com/role/ImpairmentExpenseDetails Impairment Expense (Details) Details http://www.betterforyouwellness.com/role/ImpairmentExpense 28 false false R29.htm 028 - Disclosure - Subsequent Events (Details) Sheet http://www.betterforyouwellness.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.betterforyouwellness.com/role/SubsequentEvents 29 false false All Reports Book All Reports f10q0522_betterforyou.htm bfyw-20220531.xsd bfyw-20220531_cal.xml bfyw-20220531_def.xml bfyw-20220531_lab.xml bfyw-20220531_pre.xml f10q0522ex31_better.htm f10q0522ex32_better.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 45 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q0522_betterforyou.htm": { "axisCustom": 0, "axisStandard": 9, "contextCount": 105, "dts": { "calculationLink": { "local": [ "bfyw-20220531_cal.xml" ] }, "definitionLink": { "local": [ "bfyw-20220531_def.xml" ] }, "inline": { "local": [ "f10q0522_betterforyou.htm" ] }, "labelLink": { "local": [ "bfyw-20220531_lab.xml" ] }, "presentationLink": { "local": [ "bfyw-20220531_pre.xml" ] }, "schema": { "local": [ "bfyw-20220531.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd" ] } }, "elementCount": 311, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 72, "http://www.betterforyouwellness.com/20220531": 15, "http://xbrl.sec.gov/dei/2022": 4, "total": 91 }, "keyCustom": 45, "keyStandard": 159, "memberCustom": 24, "memberStandard": 11, "nsprefix": "bfyw", "nsuri": "http://www.betterforyouwellness.com/20220531", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Going Concern", "role": "http://www.betterforyouwellness.com/role/GoingConcern", "shortName": "Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Income Taxes", "role": "http://www.betterforyouwellness.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Commitments and Contingencies", "role": "http://www.betterforyouwellness.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Convertible Note Payable", "role": "http://www.betterforyouwellness.com/role/ConvertibleNotePayable", "shortName": "Convertible Note Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "bfyw:StockPurchaseWarrantLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Stock Purchase Warrant Liability", "role": "http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiability", "shortName": "Stock Purchase Warrant Liability", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "bfyw:StockPurchaseWarrantLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Shareholder Equity", "role": "http://www.betterforyouwellness.com/role/ShareholderEquity", "shortName": "Shareholder Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Related-Party Transactions", "role": "http://www.betterforyouwellness.com/role/RelatedPartyTransactions", "shortName": "Related-Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "bfyw:ImpairmentExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Impairment Expense", "role": "http://www.betterforyouwellness.com/role/ImpairmentExpense", "shortName": "Impairment Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "bfyw:ImpairmentExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Subsequent Events", "role": "http://www.betterforyouwellness.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheet", "role": "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet", "shortName": "Consolidated Balance Sheet", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c56", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntercompanyAgreementsDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Organization and Description of Business (Details)", "role": "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "shortName": "Organization and Description of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c56", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntercompanyAgreementsDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromSubsidiariesNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Income Taxes (Details)", "role": "http://www.betterforyouwellness.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromSubsidiariesNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:PaymentsForFees", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c62", "decimals": "0", "lang": null, "name": "us-gaap:InvestmentOwnedSubjectToOptionPrice", "reportCount": 1, "unique": true, "unitRef": "usdPeritem", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c66", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Convertible Note Payable (Details)", "role": "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails", "shortName": "Convertible Note Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c67", "decimals": "2", "lang": null, "name": "us-gaap:ShortTermDebtInterestRateIncrease", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c63", "decimals": null, "first": true, "lang": "en-US", "name": "bfyw:StockPurchaseWarrantLiabilityDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Stock Purchase Warrant Liability (Details)", "role": "http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiabilityDetails", "shortName": "Stock Purchase Warrant Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c63", "decimals": null, "first": true, "lang": "en-US", "name": "bfyw:StockPurchaseWarrantLiabilityDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Shareholder Equity (Details)", "role": "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "shortName": "Shareholder Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "lang": "en-US", "name": "us-gaap:PreferredStockVotingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LoansPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Related-Party Transactions (Details)", "role": "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "shortName": "Related-Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LoansPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueAdjustment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Impairment Expense (Details)", "role": "http://www.betterforyouwellness.com/role/ImpairmentExpenseDetails", "shortName": "Impairment Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueAdjustment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Subsequent Events (Details)", "role": "http://www.betterforyouwellness.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtInstrumentMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c2", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheet (Parentheticals)", "role": "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Consolidated Balance Sheet (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "bfyw:MerchandiseSalesAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statement of Operations", "role": "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement", "shortName": "Consolidated Statement of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "bfyw:MerchandiseSalesAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statement of Operations (Parentheticals)", "role": "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Consolidated Statement of Operations (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c25", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statement of Changes in Stockholders\u2019 Equity (Deficit)", "role": "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3", "shortName": "Consolidated Statement of Changes in Stockholders\u2019 Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c25", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statement of Cash Flows", "role": "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow", "shortName": "Consolidated Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "bfyw:CommonStockIssued", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Organization and Description of Business", "role": "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0522_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 35, "tag": { "bfyw_AmandaCayemitteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AmandaCayemitteMember", "terseLabel": "Amanda Cayemitte [Member]" } } }, "localname": "AmandaCayemitteMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_BetterForYouWellnessIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BetterForYouWellnessIncMember", "terseLabel": "Better for You Wellness, Inc. [Member]" } } }, "localname": "BetterForYouWellnessIncMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_CRSConsultingLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CRSConsultingLLCMember", "terseLabel": "CRS Consulting, LLC [Member]" } } }, "localname": "CRSConsultingLLCMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_CRSConsultingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CRSConsultingsLLCMember", "terseLabel": "CRS Consulting, LLC [Member]" } } }, "localname": "CRSConsultingsLLCMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_CancellationAndReturnOfCommonShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cancellation and return of common shares.", "label": "CancellationAndReturnOfCommonShares", "terseLabel": "Cancellation and return of common shares" } } }, "localname": "CancellationAndReturnOfCommonShares", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_ClosingSharePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Closing share price.", "label": "ClosingSharePrice", "terseLabel": "Closing share price (in Dollars)" } } }, "localname": "ClosingSharePrice", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_CommitmentShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of commitment shares.", "label": "CommitmentShares", "terseLabel": "Commitment shares (in Shares)" } } }, "localname": "CommitmentShares", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "bfyw_CommitmentsandContingenciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Line Items]" } } }, "localname": "CommitmentsandContingenciesDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "bfyw_CommitmentsandContingenciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "localname": "CommitmentsandContingenciesDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "bfyw_CommonStockClosingPricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of common stock closing price.", "label": "CommonStockClosingPricePercentage", "terseLabel": "Common stock closing price, percentage" } } }, "localname": "CommonStockClosingPricePercentage", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "percentItemType" }, "bfyw_CommonStockConversionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock conversion price per share.", "label": "CommonStockConversionPricePerShare", "terseLabel": "Common stock conversion price per share (in Dollars per share)" } } }, "localname": "CommonStockConversionPricePerShare", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "perShareItemType" }, "bfyw_CommonStockIssued": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common stock issued .", "label": "CommonStockIssued", "terseLabel": "Common stock issued" } } }, "localname": "CommonStockIssued", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_CommonStockSharesReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of common stock shares received", "label": "CommonStockSharesReceived", "terseLabel": "Common stock shares received (in Shares)" } } }, "localname": "CommonStockSharesReceived", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ImpairmentExpenseDetails" ], "xbrltype": "sharesItemType" }, "bfyw_ConsultingAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting agreement description.", "label": "ConsultingAgreementDescription", "terseLabel": "Consulting agreement, description" } } }, "localname": "ConsultingAgreementDescription", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "bfyw_ConversionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion price per share.", "label": "ConversionPricePerShare", "terseLabel": "Conversion price per share (in Dollars per share)" } } }, "localname": "ConversionPricePerShare", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "bfyw_ConvertibleNotePayableDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Payable (Details) [Line Items]" } } }, "localname": "ConvertibleNotePayableDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "stringItemType" }, "bfyw_ConvertibleNotePayableDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Payable (Details) [Table]" } } }, "localname": "ConvertibleNotePayableDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "stringItemType" }, "bfyw_ConvertibleNotePayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Payable Disclosure [Abstract]" } } }, "localname": "ConvertibleNotePayableLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayable" ], "xbrltype": "stringItemType" }, "bfyw_ConvertibleNotePayableTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Payable [Table]" } } }, "localname": "ConvertibleNotePayableTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayable" ], "xbrltype": "stringItemType" }, "bfyw_CoverExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cover expenses.", "label": "CoverExpenses", "terseLabel": "Cover expenses (in Dollars)" } } }, "localname": "CoverExpenses", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.betterforyouwellness.com/20220531", "xbrltype": "stringItemType" }, "bfyw_DrNicolaFinleyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DrNicolaFinleyMember", "terseLabel": "Dr. Nicola Finley [Member]" } } }, "localname": "DrNicolaFinleyMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "bfyw_ExercisePricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of exercise price.", "label": "ExercisePricePercentage", "terseLabel": "Exercise price percentage" } } }, "localname": "ExercisePricePercentage", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "bfyw_ExpensesContributedToCapital": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses contributed to capital.", "label": "ExpensesContributedToCapital", "terseLabel": "Expenses contributed to capital" } } }, "localname": "ExpensesContributedToCapital", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_FairMarketValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of fair market value.", "label": "FairMarketValue", "terseLabel": "Fair market value (in Dollars)" } } }, "localname": "FairMarketValue", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_FastTrackSolutionsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FastTrackSolutionsIncMember", "terseLabel": "Fast Track Solutions, Inc. [Member]" } } }, "localname": "FastTrackSolutionsIncMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_GoingConcernLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern [Abstract]" } } }, "localname": "GoingConcernLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/GoingConcern" ], "xbrltype": "stringItemType" }, "bfyw_GoingConcernTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern [Table]" } } }, "localname": "GoingConcernTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/GoingConcern" ], "xbrltype": "stringItemType" }, "bfyw_GreenOhioVenturesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GreenOhioVenturesLLCMember", "terseLabel": "Green Ohio Ventures, LLC [Member]" } } }, "localname": "GreenOhioVenturesLLCMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_IanJamesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IanJamesMember", "terseLabel": "Ian James [Member]" } } }, "localname": "IanJamesMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "bfyw_ImpairmentExpense": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment expense.", "label": "ImpairmentExpense", "terseLabel": "Impairment expense" } } }, "localname": "ImpairmentExpense", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_ImpairmentExpenseDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Impairment Expense (Details) [Line Items]" } } }, "localname": "ImpairmentExpenseDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ImpairmentExpenseDetails" ], "xbrltype": "stringItemType" }, "bfyw_ImpairmentExpenseDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Impairment Expense (Details) [Table]" } } }, "localname": "ImpairmentExpenseDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ImpairmentExpenseDetails" ], "xbrltype": "stringItemType" }, "bfyw_ImpairmentExpenseDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Impairment Expense Disclosure [Abstract]" } } }, "localname": "ImpairmentExpenseDisclosureAbstract", "nsuri": "http://www.betterforyouwellness.com/20220531", "xbrltype": "stringItemType" }, "bfyw_ImpairmentExpenseDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for impairment expense.", "label": "ImpairmentExpenseDisclosureTextBlock", "terseLabel": "Impairment Expense" } } }, "localname": "ImpairmentExpenseDisclosureTextBlock", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ImpairmentExpense" ], "xbrltype": "textBlockItemType" }, "bfyw_ImpairmentExpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Impairment Expense [Abstract]" } } }, "localname": "ImpairmentExpenseLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ImpairmentExpense" ], "xbrltype": "stringItemType" }, "bfyw_ImpairmentExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Impairment Expense [Table]" } } }, "localname": "ImpairmentExpenseTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ImpairmentExpense" ], "xbrltype": "stringItemType" }, "bfyw_IncreaseDecreaseInAccruedExpenses.": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued expenses.", "label": "IncreaseDecreaseInAccruedExpenses.", "negatedLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedExpenses.", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_JeffreyDeNunzioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JeffreyDeNunzioMember", "terseLabel": "Jeffrey DeNunzio [Member]" } } }, "localname": "JeffreyDeNunzioMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_MRKTSGroupIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MRKTSGroupIncMember", "terseLabel": "MRKTS Group Inc [Member]" } } }, "localname": "MRKTSGroupIncMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_MangoMoiLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MangoMoiLLCMember", "terseLabel": "Mango Moi, LLC [Member]" } } }, "localname": "MangoMoiLLCMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ImpairmentExpenseDetails", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_MangoMoisAssetsAndTookMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MangoMoisAssetsAndTookMember", "terseLabel": "Mango Moi\u2019s assets and took [Member]" } } }, "localname": "MangoMoisAssetsAndTookMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ImpairmentExpenseDetails" ], "xbrltype": "domainItemType" }, "bfyw_MangoMoisDebtsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MangoMoisDebtsMember", "terseLabel": "Mango Moi\u2019s debts [Member]" } } }, "localname": "MangoMoisDebtsMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ImpairmentExpenseDetails" ], "xbrltype": "domainItemType" }, "bfyw_MastHillFundLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MastHillFundLPMember", "terseLabel": "Mast Hill Fund, L.P., [Member]" } } }, "localname": "MastHillFundLPMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "domainItemType" }, "bfyw_MerchandiseSalesAmount": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Merchandise sales amount.", "label": "MerchandiseSalesAmount", "terseLabel": "Merchandise Sales" } } }, "localname": "MerchandiseSalesAmount", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "bfyw_NotesPayables": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of notes payable.", "label": "NotesPayables", "negatedLabel": "Notes payable" } } }, "localname": "NotesPayables", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_OrganizationandDescriptionofBusinessDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business (Details) [Line Items]" } } }, "localname": "OrganizationandDescriptionofBusinessDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "bfyw_OrganizationandDescriptionofBusinessDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business (Details) [Table]" } } }, "localname": "OrganizationandDescriptionofBusinessDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "bfyw_PaulMoodyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PaulMoodyMember", "terseLabel": "Paul Moody [Member]" } } }, "localname": "PaulMoodyMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_PredecessorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PredecessorsMember", "terseLabel": "Predecessor [Member]" } } }, "localname": "PredecessorsMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_PreferredSharesIssuedAfterReorganization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of preferred shares issued after reorganization.", "label": "PreferredSharesIssuedAfterReorganization", "terseLabel": "Series A preferred shares issued after reorganization" } } }, "localname": "PreferredSharesIssuedAfterReorganization", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "bfyw_PreferredSharesIssuedAfterReorganizationinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of preferred shares issued after reorganization.", "label": "PreferredSharesIssuedAfterReorganizationinShares", "terseLabel": "Series A preferred shares issued after reorganization (in Shares)" } } }, "localname": "PreferredSharesIssuedAfterReorganizationinShares", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "bfyw_PreferredStocksIssued": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Preferred stock issued.", "label": "PreferredStocksIssued", "terseLabel": "Preferred stock issued" } } }, "localname": "PreferredStocksIssued", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_PurchaseOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase of common stock.", "label": "PurchaseOfCommonStock", "terseLabel": "Common stock value (in Dollars)" } } }, "localname": "PurchaseOfCommonStock", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_PurchasePriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PurchasePriceMember", "terseLabel": "Purchase Price [Member]" } } }, "localname": "PurchasePriceMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_PurchasePriceOfShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of purchase price of shares.", "label": "PurchasePriceOfShares", "terseLabel": "Purchase price of shares (in Dollars)" } } }, "localname": "PurchasePriceOfShares", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_PurchasePricePerShareEqualToPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage to purchase price per share equal.", "label": "PurchasePricePerShareEqualToPercentage", "terseLabel": "Purchase price per share equal to percentage" } } }, "localname": "PurchasePricePerShareEqualToPercentage", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "bfyw_RelatedPartiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for related parties.", "label": "RelatedPartiesPolicyTextBlock", "terseLabel": "Related Parties" } } }, "localname": "RelatedPartiesPolicyTextBlock", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "bfyw_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related-Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "bfyw_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related-Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "bfyw_RelatedPartyTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related-Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactions" ], "xbrltype": "stringItemType" }, "bfyw_RelatedPartyTransactionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related-Party Transactions [Table]" } } }, "localname": "RelatedPartyTransactionsTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactions" ], "xbrltype": "stringItemType" }, "bfyw_RestrictedCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares restricted common stock.", "label": "RestrictedCommonStock", "terseLabel": "Shares of restricted common stock" } } }, "localname": "RestrictedCommonStock", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_RestrictedCommonStocks": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Common Stocks.", "label": "RestrictedCommonStocks", "terseLabel": "Restricted common stock" } } }, "localname": "RestrictedCommonStocks", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_SRAXIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SRAXIncMember", "terseLabel": "SRAX [Member]", "verboseLabel": "SRAX, Inc [Member]" } } }, "localname": "SRAXIncMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_SauerEnergyIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SauerEnergyIncMember", "terseLabel": "Sauer Energy, Inc. [Member]" } } }, "localname": "SauerEnergyIncMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SecuritiesPurchaseAgreementMember", "terseLabel": "Securities Purchase Agreement [Member]" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "bfyw_ShareholderEquityDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity (Details) [Line Items]" } } }, "localname": "ShareholderEquityDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderEquityDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity (Details) [Table]" } } }, "localname": "ShareholderEquityDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity [Abstract]" } } }, "localname": "ShareholderEquityLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquity" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity [Table]" } } }, "localname": "ShareholderEquityTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquity" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderOwningPreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ShareholderOwningPreferredStock", "terseLabel": "Shareholder owning preferred stock" } } }, "localname": "ShareholderOwningPreferredStock", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "bfyw_SharesCancelable": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of shares cancelable.", "label": "SharesCancelable", "terseLabel": "Shares Cancelable" } } }, "localname": "SharesCancelable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "bfyw_SharesCancelableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesCancelableMember", "terseLabel": "Shares Cancelable" } } }, "localname": "SharesCancelableMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "bfyw_SharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesOfCommonStock", "terseLabel": "Shares of common stock" } } }, "localname": "SharesOfCommonStock", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "bfyw_SharesOfRestrictedCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesOfRestrictedCommonStock", "terseLabel": "Shares of restricted common stock" } } }, "localname": "SharesOfRestrictedCommonStock", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "bfyw_StephenLetourneauMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "StephenLetourneauMember", "terseLabel": "Stephen Letourneau [Member]" } } }, "localname": "StephenLetourneauMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_StockBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of stock-based compensation.", "label": "StockBasedCompensation", "terseLabel": "Stock-based compensation" } } }, "localname": "StockBasedCompensation", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_StockIssuedDuringPeriodShareNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "StockIssuedDuringPeriodShareNewIssues", "terseLabel": "Series A preferred stock were issued" } } }, "localname": "StockIssuedDuringPeriodShareNewIssues", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_StockIssuedDuringPeriodSharesCommonSharesCanceledAndReturnedToTheCompanyinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of common shares canceled and returned to the Company.", "label": "StockIssuedDuringPeriodSharesCommonSharesCanceledAndReturnedToTheCompanyinShares", "terseLabel": "Common shares canceled and returned to the Company (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesCommonSharesCanceledAndReturnedToTheCompanyinShares", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "bfyw_StockIssuedDuringPeriodSharesCommonSharesIssuedForSharesPayableinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of common shares issued for shares payable.", "label": "StockIssuedDuringPeriodSharesCommonSharesIssuedForSharesPayableinShares", "terseLabel": "Common shares issued for shares payable (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesCommonSharesIssuedForSharesPayableinShares", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "bfyw_StockIssuedDuringPeriodSharesCommonStockPurchaseWarrantForPurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of common stock purchase warrant for purchase.", "label": "StockIssuedDuringPeriodSharesCommonStockPurchaseWarrantForPurchase", "terseLabel": "Common stock purchase warrant for purchase (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesCommonStockPurchaseWarrantForPurchase", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "sharesItemType" }, "bfyw_StockIssuedDuringPeriodValueCommonSharesCanceledAndReturnedToTheCompany": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period common shares canceled and returned to the Company.", "label": "StockIssuedDuringPeriodValueCommonSharesCanceledAndReturnedToTheCompany", "terseLabel": "Common shares canceled and returned to the Company" } } }, "localname": "StockIssuedDuringPeriodValueCommonSharesCanceledAndReturnedToTheCompany", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "bfyw_StockIssuedDuringPeriodValueCommonSharesIssuedForSharesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in common shares issued for shares payable.", "label": "StockIssuedDuringPeriodValueCommonSharesIssuedForSharesPayable", "terseLabel": "Common shares issued for shares payable" } } }, "localname": "StockIssuedDuringPeriodValueCommonSharesIssuedForSharesPayable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "bfyw_StockOptionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock option description.", "label": "StockOptionDescription", "terseLabel": "Stock option, description" } } }, "localname": "StockOptionDescription", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_StockPurchaseWarrantLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Purchase Warrant Liability [Abstract]" } } }, "localname": "StockPurchaseWarrantLiabilityAbstract", "nsuri": "http://www.betterforyouwellness.com/20220531", "xbrltype": "stringItemType" }, "bfyw_StockPurchaseWarrantLiabilityDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock purchase warrant liability description.", "label": "StockPurchaseWarrantLiabilityDescription", "terseLabel": "Stock purchase warrant liability description" } } }, "localname": "StockPurchaseWarrantLiabilityDescription", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiabilityDetails" ], "xbrltype": "stringItemType" }, "bfyw_StockPurchaseWarrantLiabilityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "StockPurchaseWarrantLiabilityTextBlock", "terseLabel": "Stock Purchase Warrant Liability" } } }, "localname": "StockPurchaseWarrantLiabilityTextBlock", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiability" ], "xbrltype": "textBlockItemType" }, "bfyw_StockWarrantLiability": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of stock warrant liability.", "label": "StockWarrantLiability", "terseLabel": "Stock warrant liability" } } }, "localname": "StockWarrantLiability", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "bfyw_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "bfyw_TotalPaymentsConsideredContributions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total payments considered contributions.", "label": "TotalPaymentsConsideredContributions", "terseLabel": "Total payments considered contributions (in Dollars)" } } }, "localname": "TotalPaymentsConsideredContributions", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_TotalUnamortizedStockOptionExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total unamortized stock option expense.", "label": "TotalUnamortizedStockOptionExpense", "terseLabel": "Total unamortized stock option expense (in Dollars)" } } }, "localname": "TotalUnamortizedStockOptionExpense", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_WarrantCoverageRaisedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of warrant coverage amount raised.", "label": "WarrantCoverageRaisedPercentage", "terseLabel": "Warrant coverage raised percentage" } } }, "localname": "WarrantCoverageRaisedPercentage", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "bfyw_WilliamsburgVentureHoldingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WilliamsburgVentureHoldingsLLCMember", "terseLabel": "Williamsburg Venture Holdings LLC [Member]" } } }, "localname": "WilliamsburgVentureHoldingsLLCMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_YapoMbeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "YapoMbeMember", "terseLabel": "Yapo M\u2019be [Member]" } } }, "localname": "YapoMbeMember", "nsuri": "http://www.betterforyouwellness.com/20220531", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]", "terseLabel": "Board of Directors [Member]" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r79", "r147", "r152", "r158", "r248", "r249", "r253", "r254", "r289", "r343" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r79", "r147", "r152", "r158", "r248", "r249", "r253", "r254", "r289", "r343" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r134", "r285" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r314", "r326" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.", "label": "Accrued Liabilities", "terseLabel": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r16", "r292" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r81", "r82", "r83", "r214", "r215", "r216", "r260" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentOfWarrantsGrantedForServices": { "auth_ref": [ "r60" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment for noncash service expenses paid for by granting of warrants.", "label": "Adjustment of Warrants Granted for Services", "terseLabel": "Warrant expense" } } }, "localname": "AdjustmentOfWarrantsGrantedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r212" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock option expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expense, after Tax", "terseLabel": "Share-based expense" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r49", "r60", "r176", "r275" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortized interest" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r60", "r141" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment expense" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r9", "r76", "r120", "r123", "r129", "r138", "r147", "r148", "r149", "r151", "r152", "r153", "r154", "r155", "r156", "r158", "r159", "r248", "r253", "r266", "r290", "r292", "r309", "r321" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r22", "r76", "r138", "r147", "r148", "r149", "r151", "r152", "r153", "r154", "r155", "r156", "r158", "r159", "r248", "r253", "r266", "r290", "r292" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.", "label": "Assets, Fair Value Adjustment", "terseLabel": "Fair market value" } } }, "localname": "AssetsFairValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ImpairmentExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r202", "r203", "r241" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r202", "r203", "r239", "r240", "r241" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Voting percentage" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r242", "r243", "r244" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Paid consideration (in Dollars)" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage", "terseLabel": "Owning, percentage" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "percentItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r8", "r62" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r54", "r62", "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Ending cash balance", "periodStartLabel": "Beginning cash balance" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r54", "r267" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r13", "r14", "r15", "r73", "r76", "r96", "r97", "r98", "r100", "r102", "r108", "r109", "r110", "r138", "r147", "r152", "r153", "r154", "r158", "r159", "r183", "r184", "r186", "r190", "r196", "r266", "r348" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r143", "r144", "r145", "r146", "r342" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r81", "r82", "r260" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Shares", "verboseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock, No Par Value", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockOtherSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.", "label": "Common Stock, Other Shares, Outstanding", "terseLabel": "Common shares, outstanding", "verboseLabel": "Common stock value (in Shares)" } } }, "localname": "CommonStockOtherSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "verboseLabel": "Shares of common stock" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r196" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15", "r292" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock ($.0001 par value, 500,000,000 shares authorized, 380,108,169 and 370,747,042issued and outstanding as of May 31, 2022 and February 28, 2022, respectively)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r70", "r250" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockDescription": { "auth_ref": [ "r65", "r66", "r67" ], "lang": { "en-us": { "role": { "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Description", "terseLabel": "Purchase agreement description" } } }, "localname": "ConversionOfStockDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Convertible Note Payable" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r45", "r76", "r138", "r147", "r148", "r149", "r152", "r153", "r154", "r155", "r156", "r158", "r159", "r266" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of Goods Sold" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r10", "r11", "r12", "r75", "r79", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r179", "r180", "r181", "r277", "r310", "r311", "r320" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r160", "r178", "r179", "r276", "r277", "r278" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r27", "r177", "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r28", "r163", "r263" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r29", "r75", "r79", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r179", "r180", "r181", "r277" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentRepurchaseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value amount of debt instrument that was repurchased.", "label": "Debt Instrument, Repurchase Amount", "terseLabel": "Purchase price" } } }, "localname": "DebtInstrumentRepurchaseAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r167", "r275", "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Discount amount", "verboseLabel": "Original issue discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": { "auth_ref": [ "r227", "r228" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.", "label": "Deferred Tax Assets, Capital Loss Carryforwards", "terseLabel": "Deferred tax asset" } } }, "localname": "DeferredTaxAssetsCapitalLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "terseLabel": "Stock Warrant liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r23", "r78", "r150", "r152", "r153", "r157", "r158", "r159", "r283" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Loans to company \u2013 related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r41", "r86", "r87", "r88", "r89", "r90", "r94", "r96", "r100", "r101", "r102", "r105", "r106", "r261", "r262", "r316", "r328" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic and Diluted net loss per common share (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r41", "r86", "r87", "r88", "r89", "r90", "r96", "r100", "r101", "r102", "r105", "r106", "r261", "r262", "r316", "r328" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Basic and Diluted net loss per common share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r103", "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic Earnings (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r77", "r221", "r233" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Effective statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r36", "r37", "r38", "r81", "r82", "r83", "r85", "r91", "r93", "r107", "r140", "r196", "r198", "r214", "r215", "r216", "r230", "r231", "r260", "r268", "r269", "r270", "r271", "r272", "r273", "r279", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Excess Stock, Shares Issued", "terseLabel": "Shares of common stock" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r60", "r182" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Stock warrant expense" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r43", "r76", "r120", "r122", "r125", "r128", "r130", "r138", "r147", "r148", "r149", "r152", "r153", "r154", "r155", "r156", "r158", "r159", "r266" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfRetainedInterest": { "auth_ref": [ "r60", "r139" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings to reduce the carrying value of an interest continued to be held by the transferor in a securitized financial instrument.", "label": "Impairment of Retained Interest", "terseLabel": "Impairment expense" } } }, "localname": "ImpairmentOfRetainedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ImpairmentExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromSubsidiariesNetOfTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) of subsidiary attributable to the parent entity.", "label": "Income (Loss) from Subsidiaries, Net of Tax", "terseLabel": "Net loss" } } }, "localname": "IncomeLossFromSubsidiariesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r77", "r222", "r223", "r226", "r232", "r234", "r235", "r236", "r237" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r35", "r219", "r220", "r223", "r224", "r225", "r229" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r56", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in current assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r59" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntercompanyAgreementsDescription": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Description of product support, consulting, business, or other advisory service agreements entered into between the managing member or general partner and the LLC or LP, affiliate of the managing member or general partner, or affiliate of the LLC or LP. Includes a description of the key provisions of such agreements and the amount of compensation for such services during the accounting period.", "label": "Intercompany Agreements, Description", "terseLabel": "Independent director agreements, description" } } }, "localname": "IntercompanyAgreementsDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r52", "r55", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r6", "r21", "r292" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentMaturityDate": { "auth_ref": [ "r136", "r137" ], "lang": { "en-us": { "role": { "documentation": "Maturity date of investment, in YYYY-MM-DD format.", "label": "Investment Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "InvestmentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "dateItemType" }, "us-gaap_InvestmentOwnedSubjectToOptionPrice": { "auth_ref": [ "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "The option price of the investment that is subject to option.", "label": "Investment Owned, Subject to Option, Price", "terseLabel": "Option to sell amount (in Dollars per Item)" } } }, "localname": "InvestmentOwnedSubjectToOptionPrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "perUnitItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r25", "r76", "r124", "r138", "r147", "r148", "r149", "r152", "r153", "r154", "r155", "r156", "r158", "r159", "r249", "r253", "r254", "r266", "r290", "r291" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r76", "r138", "r266", "r292", "r313", "r324" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES & STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LoanProcessingFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses paid for obtaining loans which includes expenses such as application and origination fees.", "label": "Loan Processing Fee", "terseLabel": "Paid expenses" } } }, "localname": "LoanProcessingFee", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r12", "r311", "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Loans Payable", "terseLabel": "Loans" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MajorityShareholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership.", "label": "Majority Shareholder [Member]", "terseLabel": "Shareholders [Member]" } } }, "localname": "MajorityShareholderMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketRiskBenefitInterestExpense": { "auth_ref": [ "r331", "r332", "r333", "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk.", "label": "Market Risk Benefit, Interest Expense", "terseLabel": "Company received amount" } } }, "localname": "MarketRiskBenefitInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ImpairmentExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaturityOfTimeDeposits": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of customer deposits, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Maturity of Time Deposits", "terseLabel": "Registration rights expires" } } }, "localname": "MaturityOfTimeDeposits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r31", "r76", "r138", "r147", "r152", "r153", "r154", "r158", "r159", "r266", "r312", "r323" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r54" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r54", "r58", "r61" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r33", "r34", "r38", "r40", "r61", "r76", "r84", "r86", "r87", "r88", "r89", "r92", "r93", "r99", "r120", "r122", "r125", "r128", "r130", "r138", "r147", "r148", "r149", "r152", "r153", "r154", "r155", "r156", "r158", "r159", "r262", "r266", "r315", "r327" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow", "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": { "auth_ref": [ "r44" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.", "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest", "terseLabel": "Noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r81", "r82", "r83", "r198", "r245" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r48" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income(expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Convertible note payable, net accumulated interest" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r4", "r258" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherCashEquivalentsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Other Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "OtherCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r47", "r330" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses", "negatedLabel": "Other expense", "terseLabel": "Paid expenses (in Dollars)" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r329" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "terseLabel": "Other income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Component of Operating Income [Abstract]", "terseLabel": "Other Income" } } }, "localname": "OtherIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r26", "r292" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLoansPayableLongTerm": { "auth_ref": [ "r29" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term loans classified as other, payable after one year or the operating cycle, if longer.", "label": "Other Loans Payable, Long-Term, Noncurrent", "terseLabel": "Loans payable, other" } } }, "localname": "OtherLoansPayableLongTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForFees": { "auth_ref": [ "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for fees classified as other.", "label": "Payments for Other Fees", "terseLabel": "Amount paid", "verboseLabel": "Agreement fees" } } }, "localname": "PaymentsForFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLoans": { "auth_ref": [ "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments for and related to principal collection on loans related to operating activities.", "label": "Payments for Loans", "terseLabel": "Payments" } } }, "localname": "PaymentsForLoans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Shares" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14", "r183" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14", "r183" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r14", "r292" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock ($.0001 par value, 200,000,000 shares authorized; 700,000 issued and outstanding as of May 31, 2022 and February 28, 2022)" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r14", "r197" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred Stock, Voting Rights", "terseLabel": "Preferred stock, voting rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r51" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Convertible note payable" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds total (in Dollars)" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsToMinorityShareholders": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.", "label": "Proceeds from (Payments to) Noncontrolling Interests", "terseLabel": "Noncontrolling interest" } } }, "localname": "ProceedsFromPaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Proceeds from (Repayments of) Related Party Debt", "terseLabel": "Loan to company \u2013 related party" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r33", "r34", "r38", "r53", "r76", "r84", "r92", "r93", "r120", "r122", "r125", "r128", "r130", "r138", "r147", "r148", "r149", "r152", "r153", "r154", "r155", "r156", "r158", "r159", "r247", "r251", "r252", "r256", "r257", "r262", "r266", "r317" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r142", "r292", "r318", "r325" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Equipment, net depreciation" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r201", "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "http://www.betterforyouwellness.com/role/ImpairmentExpenseDetails", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r201", "r282", "r283", "r286" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r201", "r282", "r286", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "http://www.betterforyouwellness.com/role/ImpairmentExpenseDetails", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r280", "r281", "r283", "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r198", "r292", "r322", "r337", "r339" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r81", "r82", "r83", "r85", "r91", "r93", "r140", "r214", "r215", "r216", "r230", "r231", "r260", "r334", "r336" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r71", "r72" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r39", "r76", "r118", "r119", "r121", "r126", "r127", "r131", "r132", "r133", "r138", "r147", "r148", "r149", "r152", "r153", "r154", "r155", "r156", "r158", "r159", "r266", "r317" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold", "terseLabel": "Annual salary of payable" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of shares" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r46" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r13", "r14", "r196" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A", "verboseLabel": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "terseLabel": "Series of Individually Immaterial Business Acquisitions [Member]" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r59" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock options expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Grant option exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Stock option exercise price (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Stock option outstanding intrinsic value (in Dollars)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r204", "r207", "r208", "r209", "r210", "r211", "r217", "r218" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Stock price (in Dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number", "terseLabel": "Number of vested shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Stock option expire term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Stock options fair value the grant date (in Dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Transfer of shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balances (in Shares)", "periodStartLabel": "Balances (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtInterestRateIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage increase in the stated interest rate on a short-term debt instrument.", "label": "Short-Term Debt, Interest Rate Increase", "terseLabel": "Interest rate" } } }, "localname": "ShortTermDebtInterestRateIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r69", "r80" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r13", "r14", "r15", "r73", "r76", "r96", "r97", "r98", "r100", "r102", "r108", "r109", "r110", "r138", "r147", "r152", "r153", "r154", "r158", "r159", "r183", "r184", "r186", "r190", "r196", "r266", "r348" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r30", "r36", "r37", "r38", "r81", "r82", "r83", "r85", "r91", "r93", "r107", "r140", "r196", "r198", "r214", "r215", "r216", "r230", "r231", "r260", "r268", "r269", "r270", "r271", "r272", "r273", "r279", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r81", "r82", "r83", "r107", "r296" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r14", "r15", "r198" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Commitment shares (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Common shares issued for services (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r14", "r15", "r196", "r198" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Common shares issued after reorganization (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Common shares issued for purchase of subsidiary (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r196", "r198" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Shares of restricted common stock" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Common shares issued for services", "verboseLabel": "Purchase price" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r14", "r15", "r196", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Expenses paid on behalf of the Company and contributed to capital", "verboseLabel": "Expenses paid on behalf of the Company and contributed to capital (in Dollars)" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Common shares issued after reorganization" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Value, Purchase of Assets", "terseLabel": "Common shares issued for purchase of subsidiary" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Stock or Unit Option Plan Expense", "terseLabel": "The total stock option expense (in Dollars)" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r18", "r19", "r76", "r135", "r138", "r266", "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balances" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 Equity (Deficit)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r37", "r76", "r81", "r82", "r83", "r85", "r91", "r138", "r140", "r198", "r214", "r215", "r216", "r230", "r231", "r245", "r246", "r255", "r260", "r266", "r268", "r269", "r273", "r279", "r335", "r336" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodStartLabel": "Balances", "totalLabel": "Total Stockholders\u2019 Equity (Deficit)" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r74", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r198", "r200", "r259" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholder Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r274", "r294" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r274", "r294" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r274", "r294" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r293", "r295" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Table Text Block Supplement [Abstract]" } } }, "localname": "TableTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockPreferredShares": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued preferred shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Preferred, Shares", "terseLabel": "Purchase common shares (in Shares)" } } }, "localname": "TreasuryStockPreferredShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r111", "r112", "r113", "r114", "r115", "r116", "r117" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r95", "r102" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of common shares outstanding - Basic and Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r94", "r102" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares outstanding - Basic and Diluted (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "325", "URI": "https://asc.fasb.org/extlink&oid=123585653&loc=d3e44297-111616" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r218": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r237": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r258": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r288": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "7B", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782768-158439" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "13K", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783743-158441" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "29G", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819547-158441" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14.4(b))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611322-123010" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r344": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r345": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r346": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r347": { "Name": "Industry Guide", "Number": "3", "Paragraph": "D-E", "Publisher": "SEC", "Section": "V" }, "r348": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r349": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r350": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" } }, "version": "2.1" } ZIP 46 0001213900-22-045945-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-045945-xbrl.zip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
  •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end